Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos).
• IKZF IKAROS Family Zinc Finger
• the disclosure further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions associated with one or more IKZF proteins, e.g., an IKZF2 and/or IKZF4 associated disease or condition where reduction of IKZF2 and/or IKZF4 protein levels can ameliorate the disease or disorder.
• the IKAROS family of transcription factors includes five members: Ikaros (IKZF1), Helios (IKZF2), Aiolos (IKZF3), Eos (IKZF4), and Pegasus (IKZF5).
• Helios is about 50% identical with Ikaros, Aiolos, and Eos, and binds to the same DNA consensus site. When co-expressed in cells these four IKZF proteins can heterodimerize with each other. While Ikaros, Helios, and Aiolos are predominantly expressed in hematopoietic cells, Eos and Pegasus are more widely expressed across different tissues.
• Tregs Regulatory T cells
• Treg activity can also repress antitumor immune responses.
• Helios is believed to be required to maintain a stable Treg phenotype, especially in the context of inflammatory tumor microenvironments.
• Genetic Helios knockout in Tregs has been shown to reduce Treg immunosuppressive activity and induce an effector T cell phenotype.
• a first generation of small molecule Helios degraders has shown similar effects. As such Helios has emerged as a promising immuno-oncology target.
• Helios degraders are expected to be useful for the treatment of chronic viral infections, which are also characterized by the presence of elevated levels of activated Tregs.
• the present disclosure provides compounds useful as degraders of IKAROS Family Zinc Finger (IKZF) protein 2 (IKZF2; Helios).
• IKZF2 IKAROS Family Zinc Finger
• the disclosure further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding and degradation of IKZF2 protein by said compounds.
• compositions comprising a compound provided herein, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
• the pharmaceutical compositions comprise a therapeutically effective amount of a compound provided herein, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
• the pharmaceutical compositions provided herein further comprise one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, or pharmaceutically acceptable salts thereof.
• the pharmaceutical compositions further comprise a therapeutically effective amount of the one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, or pharmaceutically acceptable salts thereof.
• the present disclosure provides methods of degrading IKZF2 protein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
• a compound provided herein e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
• the present disclosure provides methods of treating a patient having an IKZF2 protein mediated condition, comprising administering to the patient a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
• a compound provided herein e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
• the present disclosure relates to degraders of IKAROS Family Zinc Finger (IKZF) proteins, such as IKZF2 (Helios).
• IKZF2 IKZF2 (Helios).
• the disclosure also relates to compositions and methods relating to IKZF2 protein degraders and the use of such compounds for treatment and/or prophylaxis of IKZF2-mediated diseases and conditions.
• the disclosure also relates to compositions and methods of treating and/or preventing cancer or viral infections that include an IKZF2 protein degrader in combination with one or more additional therapeutic agents.
• IKZF2-mediated diseases such as cancer and viral infections
• IKZF2 protein degrader and optionally one or more additional therapeutic agents.
• a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
• —CONH 2 is attached through the carbon atom.
• a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
• a wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
• a solid line coming out of the center of a ring indicates that the point of attachment for a substituent on the ring can be at any ring atom.
• Ra in the below structure can be attached to any of the five carbon ring atoms or Ra can replace the hydrogen attached to the nitrogen ring atom:
• C u-v indicates that the following group has from u to v carbon atoms.
• C 1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
• x-y membered rings wherein x and y are numerical ranges, such as “3 to 12-membered heterocyclyl”, refers to a ring containing x-y atoms (e.g., 3-12), of which up to 80% may be heteroatoms, such as N, O, S, P, and the remaining atoms are carbon.
• a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, or alkylyl group, an “arylene” group or an “arylenyl” group, or arylyl group, respectively.
• a compound disclosed herein” or “a compound of the present disclosure” or “a compound provided herein” or “a compound described herein” refers to the compounds of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe). Also included are the specific compounds of Examples 1 to 98 provided herein.
• references to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
• the term “about” includes the indicated amount ⁇ 10%.
• the term “about” includes the indicated amount ⁇ 5%.
• the term “about” includes the indicated amount ⁇ 1%.
• to the term “about X” includes description of “X”.
• the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise.
• reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
• Alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C 1-6 alkyl), 1 to 4 carbon atoms (i.e., C 1-4 alkyl), or 1 to 3 carbon atoms (i.e., C 1-3 alkyl).
• alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
• butyl includes n-butyl (i.e., —(CH 2 ) 3 CH 3 ), sec-butyl (i.e., —CH(CH 3 )CH 2 CH 3 ), isobutyl (i.e., —CH 2 CH(CH 3 ) 2 ) and tert-butyl (i.e., —C(CH 3 ) 3 ); and “propyl” includes n-propyl (i.e., —(CH 2 ) 2 CH 3 ) and isopropyl (i.e., —CH(CH 3 ) 2 ).
• Haloalkyl refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halo substituent, which may be the same or different.
• C 1-4 haloalkyl is a C 1-4 alkyl wherein one or more of the hydrogen atoms of the C 1-4 alkyl have been replaced by a halo substituent.
• haloalkyl groups include but are not limited to fluoromethyl, fluorochloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and pentafluoroethyl.
• Alkenyl refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkenyl).
• alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
• Alkynyl refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkynyl).
• alkynyl also includes those groups having one triple bond and one double bond.
• acyl refers to a group —C( ⁇ O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
• R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
• Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
• Amino refers to the group —NR y R z wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted.
• R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted. Either one of R 1 , R 2 , and R 3 can serve as points of attachment.
• Aryl refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems, wherein at least one of the rings is aromatic.
• an aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
• Aryl includes a phenyl radical.
• Aryl also includes multiple fused ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having 9 to 20 carbon atoms, e.g., 9 to 16 carbon atoms, in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle).
• Such multiple fused ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple ring system.
• a certain atom-range membered aryl e.g., 6-10 membered aryl
• the atom range is for the total ring atoms of the aryl.
• a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1,2,3,4-tetrahydronaphthyl.
• aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like.
• Aryl does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
• Cycloalkyl refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems.
• the term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond).
• cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl).
• Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• fused refers to a ring which is bound to an adjacent ring.
• the fused ring system is a heterocyclyl.
• the fused ring system is a oxabicyclohexanyl.
• the fused ring system is
• Bridged refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom.
• a divalent substituent such as alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom.
• the bridged ring is a bicyclopentyl (e.g., bicyclo[1.1.1]pentyl), bicycloheptyl (e.g., bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl), or bicyclooctyl (e.g., bicyclo[2.2.2]octyl).
• the bridged ring is a bicyclopentyl (e.g., bicyclo[1.1.1]pentyl), bicycloheptyl (e.g., bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl), or bicyclooctyl (e.g., bicyclo[2.2.2]octyl).
• the bridged ring is a bicyclopentyl (e.g., bicyclo[1.1.1]pentyl), bicycloheptyl (e.g., bicyclo[2.2.1]heptyl
• “Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom.
• Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
• the spiro substituent is a spiropentanyl (spiro[a.b]pentanyl), spirohexanyl, spiroheptanyl, spirooctyl (e.g., spiro[2.5]octyl), spirononanyl (e.g., spiro[3.5]nonanyl), spirodecanyl (e.g., spiro[4.5]decanyl), or spiroundecanyl (e.g., spiro[5.5]undecanyl).
• the spiro substituent is a spiropentanyl (spiro[a.b]pentanyl), spirohexanyl, spiroheptanyl, spirooctyl (e.g., spiro[2.5]octyl), spirononanyl (e.g., spiro[3.5]n
• Halogen or “halo” includes fluoro, chloro, bromo, and iodo.
• Heteroaryl refers to an aromatic group, including groups having an aromatic tautomer or resonance structure, having a single ring, multiple rings, or multiple fused rings, with at least one heteroatom in the ring.
• the term includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the rings.
• the sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic.
• Such rings include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl.
• the term also includes multiple ring systems (e.g.
• heteroaryl groups comprising 2 or 3 rings wherein a heteroaryl group, as defined above, can be fused with one or more heteroaryls (e.g. naphthyridinyl), carbocycles (e.g. 5,6,7,8-tetrahydroquinolyl) or aryls (e.g. indazolyl) to form a multiple fused ring.
• heteroaryls e.g. naphthyridinyl
• carbocycles e.g. 5,6,7,8-tetrahydroquinolyl
• aryls e.g. indazolyl
• Such multiple fused rings may be optionally substituted with one or more (e.g. 1, 2 or 3) oxo groups on the carbocycle portions of the condensed ring.
• heteroaryl multiple fused ring can be at any position of the ring including a heteroaryl, aryl or a carbocycle portion of the ring.
• exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl and thianaphthenyl.
• the heteroaryl is
• Heteroaryl does not encompass or overlap with aryl as defined above.
• Heterocyclyl or “heterocyclic ring” or “heterocycle” refers to a single saturated or partially unsaturated ring or a multiple ring system.
• the term includes single saturated or partially unsaturated ring (e.g. 3, 4, 5, 6 or 7-membered ring) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring.
• the ring may be substituted with one or more (e.g. 1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms.
• Such rings include but are not limited to azetidinyl, tetrahydrofuranyl or piperidinyl.
• the term also includes multiple fused ring systems (e.g. ring systems comprising 2 or 3 rings) wherein a heterocycle group (as defined above) can be connected to two adjacent atoms (fused heterocycle) with one or more heterocycles (e.g. decahydronapthyridinyl), heteroaryls (e.g. 1,2,3,4-tetrahydronaphthyridinyl), carbocycles (e.g. decahydroquinolyl) or aryls.
• the point of attachment of a heterocycle multiple fused ring as defined above, can be at any position of the ring including a heterocyle, heteroaryl, aryl or a carbocycle portion of the ring.
• heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl and 1,4-benzodioxanyl.
• fused bicyclic heterocycles include, but are not limited to
• “Hydroxy” or “hydroxyl” refers to the group —OH.
• Oxo refers to the group ( ⁇ O) or (O).
• “Sulfonyl” refers to the group —S(O) 2 R c , where R c is alkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
• substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded.
• the one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof.
• the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan.
• substituted may describe other chemical groups defined herein.
• substituted aryl includes, but is not limited to, “alkylaryl.” Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.
• substituted alkyl refers to an alkyl group having one or more substituents including hydroxyl, halo, amino, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
• substituted cycloalkyl refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, alkoxy, halo, oxo, and hydroxyl
• substituted heterocyclyl refers to a heterocyclyl group having one or more substituents including alkyl, amino, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl
• substituted aryl refers to an aryl group having one or more substituents including halo, alkyl, amino, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano
• substituted heteroaryl refers to an heteroaryl group having one or more substituents including alkyl, amino, haloalkyl,
• the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted.
• the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
• a substituted cycloalkyl, a substituted heterocyclyl, a substituted aryl, and/or a substituted heteroaryl includes a cycloalkyl, a heterocyclyl, an aryl, and/or a heteroaryl that has a substituent on the ring atom to which the cycloalkyl, heterocyclyl, aryl, and/or heteroaryl is attached to the rest of the compound.
• the cyclopropyl is substituted with a methyl group:
• the compounds of the present disclosure can be in the form of a pharmaceutically acceptable salt.
• pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids.
• the compounds of the present disclosure can be in the form of a pharmaceutically acceptable salt.
• pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids.
• the disclosure also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
• the compounds of the present disclosure which contain acidic groups can be present on these groups and can be used according to the disclosure, for example, as alkali metal salts, alkaline earth metal salts or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine, amino acids, or other bases known to persons skilled in the art.
• the compounds of the present disclosure which contain one or more basic groups, i.e., groups which can be protonated, can be present and can be used according to the disclosure in the form of their addition salts with inorganic or organic acids.
• acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to persons skilled in the art.
• the disclosure also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
• inner salts or betaines zwitterions
• the respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
• the present disclosure also includes all salts of the compounds of the present disclosure which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
• Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts are known to one of skill in the art.
• methods of preparing pharmaceutically acceptable salts from an underlying compound are known to one of skill in the art and are disclosed in for example, Berge, at al. Journal of Pharmaceutical Science, January 1977 vol. 66, No. 1, and other sources.
• tautomerism e.g., keto-enol tautomerism
• prodrugs e.g., the individual forms, like, e.g., the keto and enol form, are each within the scope of the disclosure as well as their mixtures in any ratio.
• stereoisomers like, e.g., enantiomers, cis/trans isomers, diastereomers, conformers, and the like.
• protecting group refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole.
• Chemical protecting groups and strategies for protection/deprotection are well known in the art. See e.g., Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion.
• the term “deprotecting” refers to removing the protecting group.
• solvates such as those which include as solvate water, or pharmaceutically acceptable solvates, such as alcohols, in particular ethanol.
• a “solvate” is formed by the interaction of a solvent and a compound.
• optical isomers in certain embodiments, provided are optical isomers, racemates, or other mixtures thereof of the compounds described herein or a pharmaceutically acceptable salt or a mixture thereof.
• isomers can be separated by methods well known in the art, e.g., by liquid chromatography.
• the single enantiomer or diastereomer, i.e., optically active form can be obtained by asymmetric synthesis or by resolution.
• Resolution can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using for example, a chiral high-pressure liquid chromatography (HPLC) column.
• HPLC high-pressure liquid chromatography
• stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
• the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
• “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).
• Compounds disclosed herein and their pharmaceutically acceptable salts may, in some embodiments, include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. Some embodiments include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and ( ⁇ ), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
• a “scalemic mixture” is a mixture of stereoisomers at a ratio other than 1:1.
• compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
• any formula or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
• Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
• isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphoros, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I.
• isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H, 13 C and 14 C are incorporated.
• Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
• Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
• the disclosure also includes “deuterated analogs” of compounds disclosed herein, in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
• deuterium in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
• Such compounds may exhibit increased resistance to metabolism and thus be useful for increasing the half-life of any compound of Formula (I) when administered to a mammal, e.g., a human. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984).
• Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
• Deuterium labelled or substituted therapeutic compounds of the disclosure may have beneficial DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index.
• An 18 F labeled compound may be useful for PET or SPECT studies.
• the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
• any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
• a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition.
• any atom specifically designated as a deuterium (D) is meant to represent deuterium.
• compositions comprising a compound of the present disclosure, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.
• “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present disclosure can encompass any composition made by admixing at least one compound of the present disclosure and a pharmaceutically acceptable carrier.
• “pharmaceutically acceptable carrier” includes excipients or agents such as solvents, diluents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like that are not deleterious to the disclosed compound or use thereof.
• excipients or agents such as solvents, diluents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like that are not deleterious to the disclosed compound or use thereof.
• the use of such carriers and agents to prepare compositions of pharmaceutically active substances is well known in the art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
• IC 50 or “EC 50 ” refers to the inhibitory concentration required to achieve 50% of the maximum desired effect. In many cases here the maximum desired effect is the degradation of IKZF2 protein. This term is obtained using an in vitro protein degradation assay, such as a HiBiT protein tagging assay, evaluating the concentration-dependent degradation of IKZF2 protein. “D max ” refers to the maximum protein (e.g., IKZF2 or IKZF1 protein) degradation at the highest compound concentration tested in the assay.
• Treatment is an approach for obtaining beneficial or desired results including clinical results.
• beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
• a) inhibiting the disease or condition e.g., decreasing one or more symptoms resulting from the disease or condition
• the term “treatment” or “treating” means administering a compound or pharmaceutically acceptable salt of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) for the purpose of: (i) delaying the onset of a disease, that is, causing the clinical symptoms of the disease not to develop or delaying the development thereof; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms or the severity thereof.
• Prevention means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.
• Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
• an “IKZF associated disease or condition” means a reduction of IKZF protein levels (e.g., IKZF2 or IKZF4 protein levels) can ameliorate the disease or disorder.
• IKZF associated disease or condition degradation of IKZF2 protein can ameliorate the disease or disorder.
• IKZF associated disease or condition degradation of IKZF2 protein and one or more additional IKZF proteins can ameliorate the disease or disorder.
• in an IKZF associated disease or condition degradation of IKZF4 protein can ameliorate the disease or disorder.
• Subject refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications.
• the subject is a mammal.
• the subject is a human.
• terapéuticaally effective amount or “effective amount” of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression.
• a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to IKZF2 degraders.
• the therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
• a “degrader” or “protein degrader” refers to any agent that is capable of binding to and inducing the degradation of a protein.
• protein degraders are believed to induce targeted protein degradation through recruitment of the cellular ubiquitinylation and proteasomal protein degradation machinery.
• an “IKF2 degrader” or “IKZF2 protein degrader” refers to any agent that is capable of binding to and inducing the degradation of IKZF2 protein.
• the IKZF2 degrader is IKZF2 selective.
• the IKZF2 degrader can induce degradation of IKZF2 protein and one or more additional IKZF2 proteins (e.g., IKZF1 or IKZF4).
• IKZF2 also known as Helios, is an IKAROS family zinc finger transcription factor commonly believed to be required to maintain a stable Treg cell phenotype, especially in inflammatory tumor microenvironments.
• IKZF2 or Helios protein is encoded by the IKZF2 gene.
• Exemplary reference sequences for IKZF2 include the NCBI Reference Sequences NP_001072994 (human protein), NP_035900 (mouse protein), NM_001079526 (human mRNA), and NM_0011770 (mouse mRNA).
• Related family members include IKZF1 (Ikaros; NCBI Gene ID: 10320 (human); 22778 (mouse)) and IKZF4 (Eos; NCBI Gene ID: 64375 (human); 22781 (mouse).
• IKZF e.g., IKZF2
• IKZF protein degradation is measured using a HiBiT protein tagging assay, such as the Nano Glo® HiBiT Extracellular Detection System (Promega).
• the compound of Formula (I), or pharmaceutically acceptable salt thereof is of Formula (Ia):
• X 1 and X 2 are each hydrogen.
• Y is deuterium or hydrogen. In some embodiments Y is deuterium.
• the compound of Formula (I), or pharmaceutically acceptable salt thereof is of Formula (IIa):
• R 1 is C 1-6 alkyl, C 3-12 cycloalkyl, 4 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 6-14 aryl, or 6 to 10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is unsubstituted.
• R 1 is C 1-3 alkyl, C 4-11 cycloalkyl, 6-7 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 14 aryl, 10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is unsubstituted.
• R 1 is C 1-6 alkyl, C 3-12 cycloalkyl, 4 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 6-10 aryl, or 6 to 10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is unsubstituted.
• R 1 is C 1-3 alkyl, C 4-11 cycloalkyl, 6-7 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 10 aryl, 10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is unsubstituted.
• R 1 is C 1-3 alkyl, C 4-11 cycloalkyl, 6-7 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 10 aryl, 10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is unsubstituted.
• R 1 is C 1-3 alkyl, C 4-11 cycloalkyl, 6-7 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, C 10 aryl, 10 membered heteroary
• R 1 is
• the compound is of Formula (IIb),
• R 1 is
• R 1 is
• the compound is of Formula (IIIa),
• Z 1A is unsubstituted.
• R 1 is cyclohexyl; and Z IA is unsubstituted C 1-3 alkyl or unsubstituted phenyl.
• —R 1 —O—Z 1A is
• the compound is of Formula (IIIb),
• R 1 —CO—Z 1A is
• the compound is of Formula (IIIc),
• the compound is of Formula (IIc),
• the compound is of Formula (IId),
• the compound is of Formula (IIId),
• the compound is of Formula (IIIe),
• the compound of Formula (I), or pharmaceutically acceptable salt thereof is a compound of Formula (IIe-1),
• R 1 is C 1-3 alkyl, cyclohexyl, oxaspiro[4.5]decanyl, each substituted with two Z 1 , which can be the same or different; and each Z 1 is independently hydroxy, fluoro, unsubstituted methy or unsubstituted phenyl.
• R 1 is C 1-3 alkyl or cyclohexyl, each substituted with two Z 1 , which can be the same or different; and each Z 1 is independently hydroxy, fluoro, or unsubstituted phenyl.
• —R 1 (Z 1 ) 2 is
• —R 1 (Z 1 ) 2 is
• the compound of Formula (I), or pharmaceutically acceptable salt thereof is a compound of Formula (IIe-2),
• —R 1 (Z 1 ) 3 is bicyclo[3.1.1]heptyl substituted with three Z 1 , wherein each Z 1 is unsubstituted methyl.
• the compound is of Formula (IIf),
• R 1 is piperidyl substituted with two Z 1 selected from methyl, phenyl, oxo, —C(O)O—CH 3 , and fluoro, wherein the methyl is substituted with phenyl.
• R 1 is piperidyl substituted with two Z 1 selected from methyl, oxo, and fluoro, wherein the methyl is substituted with phenyl.
• —R 1 (Z 1 )(Z 1 —Z 1A ) is
• —R 1 (Z 1 )(Z 1 —Z 1A ) is
• the compound is of Formula (IIg),
• R 1 is
• R 1 is unsubstituted C 1-3 alkyl.
• R 1 is C 1-3 alkyl, optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently hydroxy, C 6-10 aryl, or 6-10 membered heteroaryl having a nitrogen, wherein each aryl is optionally substituted with one Z IA ; and Z IA is halogen.
• R 1 is methyl, ethyl, or isopropyl, optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently hydroxy, phenyl, indolyl, or tetrahydronaphtyl, wherein each phenyl is optionally substituted with one Z IA ; and Z IA is chloro.
• R 1 is methyl, ethyl, or isopropyl, optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently hydroxy, phenyl, indolyl, or tetrahydronaphtyl, wherein each phenyl is optionally substituted with one Z IA ; and Z IA is chloro.
• R 1 is methyl, ethyl, or isopropyl, optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently hydroxy, phenyl,
• R 1 is unsubstituted C 4-6 cycloalkyl.
• R 1 is C 4 _ 6 cycloalkyl optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently cyano, hydroxy, halogen, C 1-6 alkyl, —O—Z 1A , —NH(Z 1A ), —C(O)—NH 2 , or C 6-10 aryl, wherein each alkyl or aryl is optionally substituted with one to three Z 1A , which can be the same or different; and each Z IA is independently cyano, hydroxy, halogen, C 1-6 alkyl, or C 6-10 aryl, wherein each alkyl or aryl is unsubstituted.
• R 1 is cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently cyano, hydroxy, fluoro, C 1-4 alkyl, —O—Z 1A , —NH(Z 1A ), —C(O)—NH 2 , or phenyl, wherein each alkyl is optionally substituted with one to three Z 1A , which can be the same or different; and each Z IA is independently cyano, hydroxy, halogen, C 1-3 alkyl, or phenyl, wherein each alkyl or phenyl is unsubstituted. In some embodiments R 1 is
• R 1 is
• the C 3-12 cycloalkyl of R 1 is a bicyclic C 5-11 cycloalkyl ring. In some embodiments the bicyclic C 5-11 cycloalkyl ring of R 1 is unsubstituted. In some embodiments the bicyclic C 5-11 cycloalkyl ring of R 1 is a bridged cycloalkyl ring. In some embodiments R 1 is a bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.2]octyl. In some embodiments R 1 is
• R 1 is
• the bicyclic C 5-11 cycloalkyl of R 1 is a spiro bicyclic ring.
• R 1 is a spiro[2.5]octyl, spiro[3.5]nonanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl.
• R 1 is
• R 1 is
• R 1 is 5 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, wherein the heterocyclyl is unsubstituted.
• R 1 is 5 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, optionally substituted with 1 to 2 Z 1 , which can be the same or different; each Z 1 is independently oxo, halogen, C 1-6 alkyl, —NH(Z 1A ), —C(O)—Z 1A ; —C(O)—NH—(Z 1A ), —C(O)—O—Z 1A , C 6-10 aryl, or 6-10 membered heteroaryl having a nitrogen, wherein each alkyl, aryl, or heteroaryl is optionally substituted with one Z 1A ; Z IA is halogen, C 1-6 alkyl, or C 6-10 aryl, wherein each alkyl or aryl is optionally substituted with one Z 1B ; and Z 1B is halogen or unsubstituted C 6-10 aryl.
• R 1 is pyrrolidyl, piperidyl, or tetrahydropyranyl, optionally substituted with 1 to 2 Z 1 , which can be the same or different.
• each Z 1 is independently oxo, fluoro, C 1-3 alkyl, —NH(Z 1A ), —C(O)—Z 1A ; —C(O)—NH—(Z 1A ), —C(O)—O—Z 1A , phenyl, or pyridyl, wherein each alkyl, phenyl, or pyridyl is optionally substituted with one Z 1A ;
• Z IA is C 1-3 alkyl or phenyl, wherein each alkyl or phenyl is optionally substituted with one Z 1B ; and
• Z 1B is chloro or unsubstituted phenyl.
• R 1 is
• R 1 is a bicyclic ring. In some embodiments R 1 is abridged bicyclic ring. In some embodiments R 1 is azabicyclo[2.2.1]heptanyl. In some embodiments R 1 is
• R 1 is a spiro bicyclic ring. In some embodiments R 1 is a oxaspiro[3.5]nonanyl or oxaspiro[5.5]undecanyl. In some embodiments R 1 is
• R 1 is
• R 1 is a 6 to 10 membered aryl.
• the aryl of R 1 is unsubstituted.
• the 6 to 10 membered aryl of R 1 is a bicyclic aryl ring.
• the bicyclic aryl ring of R 1 is tetrahydronaphthyl.
• R 1 is
• R 1 is
• R 1 is a 6 to 10 membered heteroaryl or heterocyclyl having a heteroatom selected from nitrogen and oxygen. In some embodiments the 6 to 10 membered heteroaryl or heterocyclyl of R 1 is unsubstituted. In some embodiments the 6 to 10 membered heteroaryl or heterocyclyl of R 1 is a bicyclic ring optionally substituted with one Z 1 ; Z 1 is C 1-3 alkyl optionally substituted with one Z 1A ; and Z 1A is unsubstituted C 6-10 aryl.
• the 6 to 10 membered heteroaryl or heterocyclyl of R 1 is tetrahydroquinolinyl or chromanyl optionally substituted with one Z 1 ;
• Z 1 is methyl optionally substituted with one Z 1A ; and
• Z 1A is unsubstituted phenyl.
• R 1 is
• each Z 1 is independently cyano, hydroxy, oxo, halogen, C 1-6 alkyl, —O—Z 1A , —C(O)—Z 1A , —C(O)—NH 2 , —C(O)—NH(Z 1A ), —C(O)—O—Z 1A , 6 to 10 membered aryl, or 5-10 membered heteroaryl having a heteroatom selected from nitrogen and oxygen.
• each Z 1 is independently cyano, hydroxy, oxo, fluoro, methyl, ethyl, propyl, n-butyl, —O—Z 1A , —C(O)—Z 1A , —C(O)—NH 2 , —C(O)—NH(Z 1A ), —C(O)—O—Z 1A , phenyl, pyridinyl, indolyl, tetryhydroquinolinyl, or chromanyl.
• each alkyl, aryl, and heteroaryl of Z 1 is unsubstituted.
• each methyl, ethyl, propyl, n-butyl, phenyl, pyridinyl, indolyl, tetryhydroquinolinyl, or chromanyl is unsubstituted.
• each Z IA is independently hydroxy, halogen, C 1-6 alkyl, or 6 to 10 membered aryl, wherein each alkyl or aryl is optionally substituted with Z 1B .
• Z 1B is unsubstituted.
• each Z IA is independently hydroxy, fluoro, chloro, methyl, ethyl, propyl, phenyl, wherein each methyl, ethyl, propyl, or phenyl is optionally substituted with one Z 1B .
• Z 1B is 6 to 10 membered aryl. In some embodiments Z 1B is phenyl. In some embodiments Z 1B is halogen. In some embodiment Z 1B is chloro.
• R 2 is hydrogen
• R 2 is C 1-3 alkyl. In some embodiments R 2 is methyl.
• the compound of Formula (I) (IId), or (IIId), or pharmaceutically acceptable salt thereof is selected from
• the compound of Formula (I) or (IIg), or pharmaceutically acceptable s alt thereof is
• the compound of Formula (I) or (IIg), or pharmaceutically acceptable salt thereof is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N-oethyl
• compositions comprising at least one compound of the present disclosure, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.
• the pharmaceutical composition of the present disclosure may additionally comprise one or more other compounds as active ingredients like a prodrug compound or other enzyme inhibitors.
• compositions are suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation) or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
• the compounds of the present disclosure can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
• the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
• any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
• oral liquid preparations such as, for example, suspensions, elixirs and solutions
• carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparation
• tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
• the active compounds can also be administered intranasally as, for example, liquid drops or spray.
• the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
• a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
• tablets may be coated with shellac, sugar or both.
• a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
• the compounds of the present disclosure may also be used as salts with various countercations to yield an orally available formulation.
• the compounds of the present disclosure may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
• Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present disclosure.
• oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
• Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
• compounds of the present disclosure are administered orally.
• kits that include a compound of the disclosure, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, and suitable packaging.
• a kit further includes instructions for use.
• a kit includes a compound of the disclosure, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
• articles of manufacture that include a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof in a suitable container.
• the container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
• the disclosure further relates to the use of compounds disclosed herein for the treatment and/or prophylaxis of diseases and/or conditions through binding and degradation of an IKZF protein (e.g., IKZF2 and/or IKZF4 protein) by said compounds. Further, the present disclosure relates to the use of said compounds for the preparation of a medicament for the treatment and/or prophylaxis of an IKZF associated disease and/or condition through binding and degradation of an IKZF protein (e.g., IKZF2 and/or IKZF4 protein) by said compounds. In some embodiments the IKZF associated disease or condition is alleviated by selective degradation of IKZF2 protein.
• an IKZF protein e.g., IKZF2 and/or IKZF4 protein
• the IKZF associated disease or condition is alleviated by degradation of IKZF2 protein. In some embodiments, the IKZF associated disease or condition is alleviated by degradation of IKZF2 protein and one or more additional IKZF proteins (e.g., IKZF1 and/or IKZF4 proteins). In some embodiments, the IKZF associated disease or condition is alleviated by degradation of IKZF4 protein.
• additional IKZF proteins e.g., IKZF1 and/or IKZF4 proteins.
• the IKZF associated disease and/or condition is an IKZF2 associated disease and/or condition. In some embodiments the IKZF2 associated disease or condition is alleviated by selective degradation of IKZF2 protein. In some embodiments the IKZF2 associated disease and/or condition is alleviated by degradation of IKZF2 protein and one or more additional IKZF proteins (e.g., IKZF1 and/or IKZF4 proteins).
• Medicaments as referred to herein can be prepared by conventional processes, including the combination of a compound according to the present disclosure and a pharmaceutically acceptable carrier.
• an IKZF protein e.g., IKZF2 protein
• a method of treating and/or preventing an IKZF protein comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof.
• a method of degrading an IKZF protein comprising administering to a patient in need thereof (e.g., a patient having an IKZF2 protein associated disease or condition) a therapeutically effective amount of a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof.
• a method of reducing the proliferation of a cell comprising contacting the cell with a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, and reducing IKZF protein (e.g., IKZF2 protein) levels in the cell.
• IKZF protein e.g., IKZF2 protein
• a method of reducing IKFZ protein e.g., IKZF2 protein
• a patient in need thereof e.g., a patient having an IKZF2 associated disease or condition
• administering comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof.
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition includes cancer.
• the cancer is a hematological cancer.
• the cancer includes a solid tumor.
• the cancer includes a malignant tumor.
• the cancer includes a metastatic cancer.
• the cancer is resistant or refractory to one or more anticancer therapies.
• greater than about 50% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so-called “hot” cancer or tumor).
• cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so called “warm” cancer or tumor). In some embodiments, less than about 1% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so called “cold” cancer or tumor).
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a hematological cancer, e.g., a leukemia (e.g., Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), B-cell ALL, Myelodysplastic Syndrome (MDS), myeloproliferative disease (MPD), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), undifferentiated leukemia), a lymphoma (e.g., small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), Waldestrom's macroglobulinemia (WM)) and/or a myelukemia (A
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition is an epithelial tumor (e.g., a carcinoma, a squamous cell carcinoma, a basal cell carcinoma, a squamous intraepithelial neoplasia), a glandular tumor (e.g., an adenocarcinoma, an adenoma, an adenomyoma), a mesenchymal or soft tissue tumor (e.g., a sarcoma, a rhabdomyosarcoma, a leiomyosarcoma, a liposarcoma, a fibrosarcoma, a dermatofibrosarcoma, a neurofibrosarcoma, a fibrous histiocytoma, an angiosarcoma, an angiomyxoma, a leiomyoma, a chondroma, a
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition includes a solid tumor in or arising from a tissue or organ, such as:
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a cancer selected from a lung cancer, a colorectal cancer, a breast cancer, a prostate cancer, a cervical cancer, a pancreatic cancer and a head and neck cancer.
• the cancer is metastatic.
• the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a cancer selected from non-small lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, and gastrointestinal stromal tumor (GIST).
• NSCLC non-small lung cancer
• TNBC triple-negative breast cancer
• NPC nasopharyngeal cancer
• mssCRC microsatellite stable colorectal cancer
• GIST gastrointestinal stromal tumor
• the cancer is metastatic.
• the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
• an IKZF protein e.g., IKZF2 protein
• the compounds of the present disclosure are given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
• the total daily dosage is from about 1 milligram to about 1000 milligrams, or from about 1 milligram to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.1 milligrams to about 200 milligrams.
• the total daily dosage is from about 1 milligram to about 900 milligrams, about 1 milligram to about 800 milligrams, about 1 milligram to about 700 milligrams, about 1 milligram to about 600 milligrams, about 1 milligram to about 400 milligrams, about 1 milligram to about 300 milligrams, about 1 milligram to about 200 milligrams, about 1 milligram to about 100 milligrams, about 1 milligram to about 50 milligrams, about 1 milligram to about 20 milligram, or about 1 milligram to about 10 milligrams.
• the compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.
• the methods provided herein comprise administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), provided herein, or pharmaceutically acceptable salt thereof, is administered in combination with one or more additional therapeutic agents to treat or prevent a disease or condition disclosed herein.
• the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents.
• the one or more additional therapeutic agents are one additional therapeutic agent.
• the one or more additional therapeutic agents are two additional therapeutic agents.
• the one or more additional therapeutic agents are two additional therapeutic agents.
• the one or more additional therapeutic agents are three additional therapeutic agents.
• the one or more additional therapeutic agents are four additional therapeutic agents.
• the pharmaceutical compositions provided herein have a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.
• the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents.
• the one or more additional therapeutic agents are one additional therapeutic agent.
• the one or more additional therapeutic agents are two additional therapeutic agents.
• the one or more additional therapeutic agents are two additional therapeutic agents.
• the one or more additional therapeutic agents are three additional therapeutic agents.
• the one or more additional therapeutic agents are four additional therapeutic agents.
• the one or more additional therapeutic agents include, e.g., an inhibitory immune checkpoint blocker or inhibitor, a stimulatory immune checkpoint stimulator, agonist or activator, a chemotherapeutic agent, an anti-cancer agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-proliferation agent, an anti-angiogenic agent, an anti-inflammatory agent, an immunotherapeutic agent, a therapeutic antigen-binding molecule (e.g., a mono- and multi-specific antibody, or fragment thereof, in any format, such as DART®, Duobody®, BiTE®, BiKE, TriKE, XmAb®, TandAb®, scFv, Fab, Fab derivative), a bi-specific antibody, a non-immunoglobulin antibody mimetic (e.g., including adnectin, affibody, affilin, affimer, affitin, alphabody, anticalin, peptide aptamer
• the one or more additional therapeutic agents include, e.g., an inhibitor, agonist, antagonist, ligand, modulator, stimulator, blocker, activator or suppressor of a target (e.g., polypeptide or polynucleotide), such as: 2′-5′-oligoadenylate synthetase (OAS1; NCBI Gene ID: 4938); 5′-3′ exoribonuclease 1 (XRN1; NCBI Gene ID: 54464); 5′-nucleotidase ecto (NT5E, CD73; NCBI Gene ID: 4907); ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1, BCR-ABL, c-ABL, v-ABL; NCBI Gene ID: 25); absent in melanoma 2 (AIM2; NCBI Gene ID: 9447); acetyl-CoA acyltransferase 2 (ACAA2
• the one or more additional therapeutic agents include, e.g., an agent targeting 5′-nucleotidase ecto (NT5E or CD73; NCBI Gene ID: 4907); adenosine A 2A receptor (ADORA2A; NCBI Gene ID: 135); adenosine A 2B receptor (ADORA2B; NCBI Gene ID: 136); C-C motif chemokine receptor 8 (CCR8, CDw198; NCBI Gene ID: 1237); cytokine inducible SH2 containing protein (CISH; NCBI Gene ID: 1154); diacylglycerol kinase alpha (DGKA, DAGK, DAGK1 or DGK-alpha; NCBI Gene ID: 1606); fms like tyrosine kinase 3 (FLT3, CD135; NCBI Gene ID: 2322); integrin associated protein (IAP, CD47; NCBI Gene ID: 961); interleukine-2 (IL
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and/or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors.
• Blockade or inhibition of inhibitory immune checkpoints can positively regulate T-cell or NK cell activation and prevent immune escape of cancer cells within the tumor microenvironment.
• the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu, et al., J Exp Clin Cancer Res . (2016) 37:110). In some embodiments, the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis, et al., Semin Immunol . (2017) 31:64-75 and Chiossone, et al., Nat Rev Immunol . (2016) 18(11):671-688).
• Treg regulatory T-cells
• Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects (e.g., reviewed in Plitas and Rudensky, Annu. Rev. Cancer Biol . (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol . (2019) 49:1140-1146).
• immune checkpoint proteins or receptors examples include CD27 (NCBI Gene ID: 939), CD70 (NCBI Gene ID: 970); CD40 (NCBI Gene ID: 958), CD40LG (NCBI Gene ID: 959); CD47 (NCBI Gene ID: 961), SIRPA (NCBI Gene ID: 140885); CD48 (SLAMF2; NCBI Gene ID: 962), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H; NCBI Gene ID: 126259), CD84 (LY9B, SLAMF5; NCBI Gene ID: 8832), CD96 (NCBI Gene ID: 10225), CD160 (NCBI Gene ID: 11126), MS4A1 (CD20; NCBI Gene ID: 931), CD244 (SLAMF4; NCBI Gene ID: 51744); CD276 (B7H3; NCBI Gene ID: 80381); V-set domain containing T cell activation inhibitor 1 (
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors.
• T-cell inhibitory immune checkpoint proteins or receptors include CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCDILG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus
• the compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors.
• T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See,
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors.
• NK-cell inhibitory immune checkpoint proteins or receptors include killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor D1 (KLRD1, CD94), killer cell lectin like receptor G1 (KLRG1; CLEC15A, MAFA, 2F1); sialic acid binding Ig like lectin 7 (SIGLEC7); and sialic acid binding I
• NK-cell stimulatory immune checkpoint proteins or receptors include CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis, et al., Semin Immunol . (2017) 31:64-75; Fang, et al., Semin Immunol . (2017) 31:37-54; and Chiossone, et al., Nat Rev Immunol . (2016) 18(11):671-688.
• the one or more immune checkpoint inhibitors comprise a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT.
• the one or more immune checkpoint inhibitors comprise a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT.
• the one or more immune checkpoint inhibitors comprise a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of LAG3.
• inhibitors of CTLA4 include ipilimumab, tremelimumab, BMS-986218, AGEN1181, zalifrelimab (AGEN1884), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002 (ipilimumab biosimilar), BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, HBM-4003, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, BPI-002, as well as multi-specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA)
• inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be co-administered include pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, cosibelimab (CK-301), sasanlimab (PF-06801591), tislelizumab (BGB-A317), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, retifanlimab (MGA-012), BI-754091, balstilimab (AGEN-2034), AMG-404, toripalimab (JS-001), cetrelimab (JNJ-63723283), geno
• inhibitors of TIGIT include tiragolumab (RG-6058), vibostolimab, domvanalimab (AB154), AB308, BMS-986207, AGEN-1307, COM-902, or etigilimab.
• inhibitors of LAG3 that can be co-administered include leramilimab (LAG525).
• Treg regulatory T-cell
• Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects. See, e.g., Plitas and Rudensky, Annu. Rev. Cancer Biol . (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol . (2019) 49:1140-1146.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, provided herein is administered with one or more inhibitors of Treg activity or a Treg depleting agent.
• Treg inhibition or depletion can augment the effect of immune checkpoint inhibitors in cancer therapeutics.
• compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more Treg inhibitors.
• the Treg inhibitor can suppress the migration of Tregs into the tumor microenvironment.
• Treg inhibitor can reduce the immunosuppressive function of Tregs.
• the Treg inhibitor can modulate the cellular phenotype and induce production of proinflammatory cytokines.
• Exemplary Treg inhibitors include, without limitation, CCR4 (NCBI Gene ID: 1233) antagonists and degraders of Ikaros zinc-finger proteins (e.g., Ikaros (IKZF1; NCBI Gene ID: 10320), Helios (IKZF2; NCBI Gene ID: 22807), Aiolos (IKZF3; NCBI Gene ID: 22806), and Eos (IKZF4; NCBI Gene ID: 64375).
• CCR4 NCBI Gene ID: 1233
• Ikaros IKZF1
• NCBI Gene ID: 10320 Helios
• IKZF2 Helios
• Aiolos IKZF3
• NCBI Gene ID: 22806 Aiolos
• Eos IKZF4; NCBI Gene ID: 64375
• Helios degraders examples include without limitation I-57 (Novartis) and compounds disclosed in WO2019038717, WO2020012334, WO20200117759, and WO2021101919.
• a compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more Treg depleting agents.
• the Treg depleting agent is an antibody.
• the Treg depleting antibody has antibody-dependent cytotoxic (ADCC) activity.
• the Treg depleting antibody is Fc-engineered to possess an enhanced ADCC activity.
• the Treg depleting antibody is an antibody-drug conjugate (ADC).
• Illustrative targets for Treg depleting agents include without limitation CD25 (IL2RA; NCBI Gene ID: 3559), CTLA4 (CD152; NCBI Gene ID: 1493); GITR (TNFRSF18; NCBI Gene ID: 8784); 4-1BB (CD137; NCBI Gene ID: 3604), OX-40 (CD134; NCBI Gene ID: 7293), LAG3 (CD223; NCBI Gene ID: 3902), TIGIT (NCBI Gene ID: 201633), CCR4 (NCBI Gene ID: 1233), and CCR8 (NCBI Gene ID: 1237).
• CD25 IL2RA
• CTLA4 CD152; NCBI Gene ID: 1493
• GITR TNFRSF18; NCBI Gene ID: 8784
• 4-1BB CD137; NCBI Gene ID: 3604
• OX-40 CD134; NCBI Gene ID: 7293
• LAG3 CD223; NCBI Gene ID: 3902
• TIGIT NCBI Gene ID: 201633
• CCR4 NCBI Gene
• the Treg inhibitor or Treg depleting agent that can be co-administered comprises an antibody or antigen-binding fragment thereof that selectively binds to a cell surface receptor selected from the group consisting of C-C motif chemokine receptor 4 (CCR4), C-C motif chemokine receptor 7 (CCR7), C-C motif chemokine receptor 8 (CCR8), C-X-C motif chemokine receptor 4 (CXCR4; CD184), TNFRSF4 (OX40), TNFRSF18 (GITR, CD357), TNFRSF9 (4-1BB, CD137), cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152), programmed cell death 1 (PDCD1, PD-1), Sialyl Lewis x (CD15s), CD27, ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; CD39), protein tyrosine phosphatase receptor type C (PTPRC; CD45), neural cell adhesion
• Treg depleting anti-CCR8 antibodies that can be administered include without limitation JTX-1811 (GS-1811) (Jounce Therapeutics, Gilead Sciences), BMS-986340 (Bristol Meyers Squibb), S-531011 (Shionogi), FPA157 (Five Prime Therapeutics), SRF-114 (Surface Oncology), HBM1022 (Harbor BioMed), I0-1 (Oncurious), and antibodies disclosed in WO2021163064, WO2020138489, and WO2021152186.
• Treg depleting anti-CCR4 antibodies examples include mogamulizumab.
• Inhibiting, depleting, or reprogramming of non-stimulatory myeloid cells in the tumor microenvironment can enhance anti-cancer immune responses (see, e.g., Binnewies et al., Nat. Med . (2016) 24(5): 541-550; WO2016049641).
• Illustrative targets for depleting or reprogramming non-stimmulatory myeloid cells include triggering receptors expressed on myeloid cells, TREM-1 (CD354, NCBI Gene ID: 54210) and TREM-2 (NCBI Gene ID: 54209).
• a compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more myeloid cell depleting or reprogramming agents, such as an anti-TREM-1 antibody (e.g. PY159; antibodies disclosed in WO2019032624) or an anti-TREM-2 antibody (e.g., PY314; antibodies disclosed in WO2019118513).
• an anti-TREM-1 antibody e.g. PY159; antibodies disclosed
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with agents targeting a cluster of differentiation (CD) marker.
• CD cluster of differentiation
• CD marker targeting agents that can be co-administered include without limitation A6, AD-IL24, neratinib, tucatinib (ONT 380), mobocertinib (TAK-788), tesevatinib, trastuzumab (HERCEPTIN®), trastuzumab biosimimar (HLX-02), margetuximab, BAT-8001, pertuzumab (Perjeta), pegfilgrastim, RG6264, zanidatamab (ZW25), cavatak, AIC-100, tagraxofusp (SL-401), HLA-A2402/HLA-A0201 restricted epitope peptide vaccine, dasatinib, imatinib, nilotinib, sorafenib, lenvatinib mesylate, ofranergene obadenovec, cabozantinib malate, AL-8326, ZLJ-
• the CD marker targeting agents that can be co-administered include small molecule inhibitors, such as PBF-1662, BLZ-945, pemigatinib (INCB-054828), rogaratinib (BAY-1163877), AZD4547, roblitinib (FGF-401), quizartinib dihydrochloride, SX-682, AZD-5069, PLX-9486, avapritinib (BLU-285), ripretinib (DCC-2618), imatinib mesylate, JSP-191, BLU-263, CD117-ADC, AZD3229, telatinib, vorolanib, GO-203-2C, AB-680, PSB-12379, PSB-12441, PSB-12425, CB-708, HM-30181A, motixafortide (BL-8040), LY2510924, burixafor (TG-0054),
• the CD marker targeting agent that can be co-administered include small molecule agonists, such as interleukin 2 receptor subunit gamma, eltrombopag, rintatolimod, poly-ICLC (NSC-301463), Riboxxon, Apoxxim, RIBOXXIM®, MCT-465, MCT-475, G100, PEPA-10, eftozanermin alfa (ABBV-621), E-6887, motolimod, resiquimod, selgantolimod (GS-9688), VTX-1463, NKTR-262, AST-008, CMP-001, cobitolimod, tilsotolimod, litenimod, MGN-1601, BB-006, IMO-8400, IMO-9200, agatolimod, DIMS-9054, DV-1079, lefitolimod (MGN-1703), CYT-003, and PUL-042.
• small molecule agonists such as inter
• the CD marker targeting agent that can be co-administered include antibodies, such as tafasitamab (MOR208; MorphoSys AG), Inebilizumab (MEDI-551), obinutuzumab, IGN-002, rituximab biosimilar (PF-05280586), varlilumab (CDX-1127), AFM-13 (CD16/CD30), AMG330, otlertuzumab (TRU-016), isatuximab, felzartamab (MOR-202), TAK-079, TAK573, daratumumab (DARZALEX®), TTX-030, selicrelumab (RG7876), APX-005M, ABBV-428, ABBV-927, mitazalimab (JNJ-64457107), lenziluma, alemtuzuma, emactuzumab, AMG-820, FPA-008 (ca) t
• the CD marker targeting agent that can be co-administered include cell therapies, such as CD19-ARTEMIS, TBI-1501, CTL-119 huCART-19 T cells, 1 iso-cel, lisocabtagene maraleucel (JCAR-017), axicabtagene ciloleucel (KTE-C19, Yescarta®), axicabtagene ciloleucel (KTE-X19), U.S. Pat. Nos.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of CD47 (IAP, MER6, OA3; NCBI Gene ID: 961).
• CD47 inhibitors examples include anti-CD47 mAbs (Vx-1004), anti-human CD47 mAbs (CNTO-7108), CC-90002, CC-90002-ST-001, humanized anti-CD47 antibody or a CD47-blocking agent, NI-1701, NI-1801, RCT-1938, ALX148, SG-404, SRF-231, and TTI-621.
• Additional exemplary anti-CD47 antibodies include CC-90002, magrolimab (Hu5F9-G4), AO-176 (Vx-1004), letaplimab (IBI-188) (letaplimab), lemzoparlimab (TJC-4), SHR-1603, HLX-24, LQ-001, IMC-002, ZL-1201, IMM-01, B6H12, GenSci-059, TAY-018, PT-240, 1F8-GMCSF, SY-102, KD-015, ALX-148, AK-117, TTI-621, TTI-622, or compounds disclosed in WO199727873, WO199940940, WO2002092784, WO2005044857, WO2009046541, WO2010070047, WO2011143624, WO2012170250, WO2013109752, WO2013119714, WO2014087248, WO2015191861, WO2016022971, WO20160230
• the CD47 inhibitor is RRx-001, DSP-107, VT-1021, IMM-02, SGN-CD47M, or SIRPa-Fc-CD40L (SL-172154). In some embodiments the CD47 inhibitor is magrolimab.
• the CD47 inhibitor is a bispecific antibodies targeting CD47, such as IBI-322 (CD47/PD-L1), IMM-0306 (CD47/CD20), TJ-L1C4 (CD47/PD-L1), HX-009 (CD47/PD-1), PMC-122 (CD47/PD-L1), PT-217, (CD47/DLL3), IMM-26011 (CD47/FLT3), IMM-0207 (CD47/VEGF), IMM-2902 (CD47/HER2), BH29xx (CD47/PD-L1), IMM-03 (CD47/CD20), IMM-2502 (CD47/PD-L1), HMBD-004B (CD47/BCMA), HMBD-004A (CD47/CD33), TG-1801 (NI-1701), or NI-1801.
• CD47 such as IBI-322 (CD47/PD-L1), IMM-0306 (CD47/CD20), TJ-L1C4 (CD47/PD
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a SIRPa targeting agent (NCBI Gene ID: 140885; UniProt P78324).
• SIRPa targeting agent NCBI Gene ID: 140885; UniProt P78324
• SIRPa targeting agents examples include SIRP ⁇ inhibitors, such as AL-008, RRx-001, and CTX-5861, and anti-SIRP ⁇ antibodies, such as FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, Q-1801 (SIRPa/PD-L1).
• SIRP ⁇ inhibitors such as AL-008, RRx-001, and CTX-5861
• anti-SIRP ⁇ antibodies such as FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, Q-1801 (SIRPa/PD-L1).
• SIRP ⁇ -targeting agents of use are described, for example, in W0200140307, WO2002092784, WO2007133811, WO2009046541, WO2010083253, WO2011076781, WO2013056352, WO2015138600, WO2016179399, WO2016205042, WO2017178653, WO2018026600, WO2018057669, WO2018107058, WO2018190719, WO2018210793, WO2019023347, WO2019042470, WO2019175218, WO2019183266, WO2020013170 and WO2020068752.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with a FLT3R agonist.
• the compound provided herein, or pharmaceutically acceptable salt thereof is administered with a FLT3 ligand.
• the compound provided herein, or pharmaceutically acceptable salt thereof is administered with a FLT3L-Fc fusion protein, e.g., as described in WO2020263830.
• the compound provided herein, or pharmaceutically acceptable salt thereof is administered with GS-3583 or CDX-301.
• the compound provided herein, or pharmaceutically acceptable salt thereof is administered with GS-3583.
• TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an agonist of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB,
• Example anti-TNFRSF4 (OX40) antibodies that can be co-administered include MEDI6469, MEDI6383, tavolixizumab (MEDI0562), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.
• Example anti-TNFRSF5 (CD40) antibodies that can be co-administered include RG7876, SEA-CD40, APX-005M, and ABBV-428.
• the anti-TNFRSF7 (CD27) antibody varlilumab (CDX-1127) is co-administered.
• Example anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include urelumab, utomilumab (PF-05082566), AGEN-2373, and ADG-106.
• the anti-TNFRSF17 (BCMA) antibody GSK-2857916 is co-administered.
• Example anti-TNFRSF18 (GITR) antibodies that can be co-administered include MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628.
• an antibody, or fragment thereof, co-targeting TNFRSF4 (OX40) and TNFRSF18 (GITR) is co-administered.
• Such antibodies are described, e.g., in WO2017096179 and WO2018089628.
• Bi-specific antibodies targeting TNFRSF family members include PRS-343 (CD-137/HER2), AFM26 (BCMA/CD16A), AFM-13 (CD16/CD30), odronextamab (REGN-1979; CD20/CD3), AMG-420 (BCMA/CD3), INHIBRX-105 (4-1BB/PDL1), FAP-4-IBBL (4-1BB/FAP), plamotamab (XmAb-13676; CD3/CD20), RG-7828 (CD20/CD3), CC-93269 (CD3/BCMA), REGN-5458 (CD3/BCMA), and IMM-0306 (CD47/CD20).
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a TGF ⁇ antagonist.
• the TGF ⁇ antagonist is a TGF ⁇ -specific antibody.
• TGF ⁇ -specific antibodies can be prepared and characterized using methods known to those of skill in the art, such as those described in PCT International Application Publication No. WO 2018/129329 and in U.S. Pat. No. 9,518,112.
• the TGF ⁇ antagonist binds to a TGF ⁇ latency-associated peptide (LAP), e.g., TGF ⁇ 1-LAP.
• LAP TGF ⁇ latency-associated peptide
• TGF ⁇ 1-LAP-specific antibodies can be prepared and characterized using methods known to those of skill in the art, such as those described in U.S. Pat. No. 8,198,412 or U.S. Pat. No. 10,017,567.
• the TGF ⁇ antagonist binds to TGF ⁇ (e.g., TGF ⁇ 1) in a context independent manner (e.g., independent of the presentation of TGF ⁇ in a specific tissue or organ).
• the TGF ⁇ antagonist binds to TGF ⁇ (e.g., TGF ⁇ 1) in a context-dependent manner.
• the TGF ⁇ antagonist blocks activation of latent TGF ⁇ (e.g., latent TGF ⁇ 1) that is localized in extracellular matrix, e.g., in connective tissue of the liver.
• the TGF ⁇ antagonist blocks activation of latent TGF ⁇ (e.g., latent TGF ⁇ 1) that is localized in the thymus, a lymph node, or in a tumor microenvironment (e.g., in a patient having liver cancer).
• the TGF ⁇ antagonist blocks activation of latent TGF ⁇ (e.g., latent TGF ⁇ 1) by Latent TGF ⁇ Binding Protein (LTBP). In some embodiments, the TGF ⁇ antagonist blocks activation of latent TGF ⁇ (e.g., latent TGF ⁇ 1) by Glycoprotein-A Repetitions Predominant protein (GARP), as described, e.g., in U.S. Pat. No. 10,000,572. In some embodiments, the TGF ⁇ antagonist is ARGX-115. In some embodiments, the TGF ⁇ antagonist is SK-181. In some embodiments, the TGF ⁇ antagonist is an anti-latency-associated peptide (LAP) antibody that specifically binds to a LAP-TGF ⁇ complex.
• LAP anti-latency-associated peptide
• the anti-LAP antibody specifically binds to LAP-TGF ⁇ complexes in extracellular matrix (ECM), e.g., of connective tissue in the liver.
• ECM extracellular matrix
• the anti-LAP antibody specifically binds to LAP-TGF ⁇ complexes on the surfaces of certain immunosuppressive cell types, such as regulatory T cells (Tregs), tumor-associated macrophages, or myeloid-derived suppressor cells, e.g., in a tumor microenvironment.
• the anti-LAP antibody is a TLS-01 antibody.
• the anti-LAP antibody specifically binds to LAP-TGF ⁇ complexes in any context.
• the anti-LAP antibody is a TLS-02 antibody.
• the TGF ⁇ antagonist comprises a TGF ⁇ receptor.
• the TGF ⁇ antagonist is a TGF ⁇ receptor-Fc fusion protein.
• the TGF ⁇ antagonist is an antibody comprising a TGF ⁇ receptor. TGF ⁇ antagonists comprising a TGF ⁇ receptor that can be useful in connection with the compositions and methods provided herein have been described, e.g., in PCT International Publication Nos. WO 2019/113123 A1 and WO 2019/113464 A1.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a bi-specific T-cell engager (e.g., not having an Fc) or an anti-CD3 bi-specific antibody (e.g., having an Fc).
• Illustrative anti-CD3 bi-specific antibodies or BiTEs that can be co-administered include duvortuxizumab (JNJ-64052781; CD19/CD3), AMG-211 (CEA/CD3), AMG-160 (PSMA/CD3), RG7802 (CEA/CD3), ERY-974 (CD3/GPC3), PF-06671008 (Cadherins/CD3), APV0436 (CD123/CD3), flotetuzumab (CD123/CD3), odronextamab (REGN-1979; CD20/CD3), MCLA-117 (CD3/CLEC12A), JNJ-0819 (heme/CD3), JNJ-7564 (CD3/heme), AMG-757 (DLL3-CD3), AMG-330 (CD33/CD3), AMG-420 (BCMA/CD3), AMG-427 (FLT3/CD3), AMG-562 (CD19/CD3), AMG
• the anti-CD3 binding bi-specific molecules may or may not have an Fc.
• Illustrative bi-specific T-cell engagers that can be co-administered target CD3 and a tumor-associated antigen as described herein, including, e.g., CD19 (e.g., blinatumomab); CD33 (e.g., AMG330); CEA (e.g., MEDI-565); receptor tyrosine kinase-like orphan receptor 1 (ROR1) (Gohil, et al., Oncoimmunology . (2017) May 17; 6(7):e1326437); PD-L1 (Horn, et al., Oncotarget. 2017 Aug. 3; 8(35):57964-57980); and EGFRvIII (Yang, et al., Cancer Lett. 2017 Sep. 10; 403:224-230).
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with a bi-specific NK-cell engager (BiKE) or a tri-specific NK-cell engager (TriKE) (e.g., not having an Fc) or bi-specific antibody (e.g., having an Fc) against an NK cell activating receptor, e.g., CD16A, C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor Fc ⁇ R (BiKE)
• Illustrative anti-CD16 bi-specific antibodies, BiKEs or TriKEs that can be co-administered include AFM26 (BCMA/CD16A) and AFM-13 (CD16/CD30).
• the anti-CD16 binding bi-specific molecules may or may not have an Fc.
• BiKEs and TriKEs are described, e.g., in Felices, et al., Methods Mol Biol. (2016) 1441:333-346; Fang, et al., Semin Immunol . (2017) 31:37-54.
• MCL1 Apoptosis Regulator, BCL2 Family Member (MCL1) Inhibitors
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of MCL1 apoptosis regulator, BCL2 family member (MCL1, TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1/EAT; NCBI Gene ID: 4170).
• MCL1 apoptosis regulator BCL2 family member
• MCL1 inhibitors examples include tapotoclax (AMG-176), AMG-397, S-64315, AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037, PRT-1419, GS-9716, and those described in WO2018183418, WO2016033486, and WO2017147410.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of protein tyrosine phosphatase non-receptor type 11 (PTPN11; BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2; NCBI Gene ID: 5781).
• SHP2 inhibitors include TNO155 (SHP-099), RMC-4550, JAB-3068, RMC-4630, and those described in WO2018172984 and WO2017211303.
• HPK1 Hematopoietic Progenitor Kinase 1
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1; NCBI Gene ID: 11184).
• mitogen-activated protein kinase kinase kinase kinase 1 mitogen-activated protein kinase kinase kinase 1
• Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors include without limitation, those described in WO2020092621, WO2018183956, WO2018183964, WO2018167147, WO2018049152, WO2020092528, WO2016205942, WO2016090300, WO2018049214, WO2018049200, WO2018049191, WO2018102366, WO2018049152, and WO2016090300.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe)provided herein, or pharmaceutically acceptable salt thereof is administered with an ASK inhibitor, e.g., mitogen-activated protein kinase kinase kinase 5 (MAP3K5; ASK1, MAPKKK5, MEKK5; NCBI Gene ID: 4217).
• ASK1 inhibitors include those described in WO2011008709 (Gilead Sciences) and WO 2013112741 (Gilead Sciences).
• BTK Bruton Tyrosine Kinase
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of Bruton tyrosine kinase (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI Gene ID: 695).
• BTK Bruton tyrosine kinase
• BTK inhibitors include (S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), zanubrutinib (BGB-3111), CB988, HM71224, ibrutinib, M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, spebrutinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, PCI-32765, and TAS-5315.
• a compound of Formula Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of cyclin dependent kinase 1 (CDK1, CDC2; CDC28A; P34CDC2; NCBI Gene ID: 983); cyclin dependent kinase 2 (CDK2, CDKN2; p33(CDK2); NCBI Gene ID: 1017); cyclin dependent kinase 3 (CDK3, NCBI Gene ID: 1018); cyclin dependent kinase 4 (CDK4, CMM3; PSK-J3; NCBI Gene ID: 1019); cyclin dependent kinase 6 (CDK6, MCPH12; PLSTIRE; NCBI Gene ID: 1021); cyclin dependent kin
• Inhibitors of CDK 1, 2, 3, 4, 6, 7 and/or 9 include abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519, dinaciclib, ibrance, FLX-925, LEE001, palbociclib, samuraciclib, ribociclib, rigosertib, selinexor, UCN-01, SY1365, CT-7001, SY-1365, G1T38, milciclib, trilaciclib, simurosertib hydrate (TAK931), and TG-02.
• DDR Discoidin Domain Receptor
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is combined with an inhibitor of discoidin domain receptor tyrosine kinase 1 (DDR1, CAK, CD167, DDR, EDDR1, HGK2, MCK10, NEP, NTRK4, PTK3, PTK3A, RTK6, TRKE; NCBI Gene ID: 780); and/or discoidin domain receptor tyrosine kinase 2 (DDR2, MIG20a, NTRKR3, TKT, TYRO10, WRCN; NCBI Gene ID: 4921).
• DDR inhibitors examples include dasatinib and those disclosed in WO2014/047624 (Gilead Sciences), US 2009-0142345 (Takeda Pharmaceutical), US 2011-0287011 (Oncomed Pharmaceuticals), WO 2013/027802 (Chugai Pharmaceutical), and WO2013/034933 (Imperial Innovations).
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a targeted E3 ligase ligand conjugate.
• Such conjugates have a target protein binding moiety and an E3 ligase binding moiety (e.g., an inhibitor of apoptosis protein (IAP) (e.g., XIAP, c-IAP1, c-IAP2, NIL-IAP, Bruce, and surviving) E3 ubiquitin ligase binding moiety, Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety, a cereblon E3 ubiquitin ligase binding moiety, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase binding moiety),and can be used to promote or increase the degradation of targeted proteins, e.g., via the ubiquitin pathway.
• IAP apoptosis protein
• VHL Von Hippel-Lindau E3 ubiquitin ligase
• MDM2 mouse double minute 2 homolog
• the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein described herein, and an E3 ligase ligand or binding moiety.
• the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein selected from Cbl proto-oncogene B (CBLB; Cbl-b, Nbla00127, RNF56; NCBI Gene ID: 868) and hypoxia inducible factor 1 subunit alpha (HIF1A; NCBI Gene ID: 3091).
• the targeted E3 ligase ligand conjugates comprise a kinase inhibitor (e.g., a small molecule kinase inhibitor, e.g., of BTK and an E3 ligase ligand or binding moiety. See, e.g., WO2018098280.
• a kinase inhibitor e.g., a small molecule kinase inhibitor, e.g., of BTK and an E3 ligase ligand or binding moiety. See, e.g., WO2018098280.
• the targeted E3 ligase ligand conjugates comprise a binding moiety targeting or binding to Interleukin-1 (IL-1) Receptor-Associated Kinase-4 (IRAK-4); Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF), c-Met/p38, or a BRD protein; and an E3 ligase ligand or binding moiety.
• IL-1 Interleukin-1
• IRAK-4 Rapidly Accelerated Fibrosarcoma
• RAF such as c-RAF, A-RAF and/or B-RAF
• c-Met/p38 c-Met/p38
• BRD protein e.g., WO2019099926, WO2018226542, WO2018119448, WO2018223909, WO2019079701.
• E3 ligase ligand conjugates that can be co-administered are described, e.g., in WO2018237026, WO2019084026, WO2019084030, WO2019067733, WO2019043217, WO2019043208, and WO2018144649.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of a histone deacetylase, e.g., histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734).
• a histone deacetylase e.g., histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734).
• HDAC inhibitors include abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620).
• IDO1 indoleamine 2,3-dioxygenase 1
• IDO1 inhibitors examples include BLV-0801, epacadostat, linrodostat (F-001287, BMS-986205), GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, and shIDO-ST, EOS-200271, KHK-2455, and LY-3381916.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of Janus kinase 1 (JAK1, JAK1A, JAK1B, JTK3; NCBI Gene ID: 3716); Janus kinase 2 (JAK2, JTK10, THCYT3; NCBI Gene ID: 3717); and/or Janus kinase 3 (JAK3, JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK; NCBI Gene ID: 3718).
• Janus kinase 1 JAK1, JAK1A, JAK1B, JTK3; NCBI Gene ID: 3716
• Janus kinase 2 JAK2, JTK10, TH
• JAK inhibitors include AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib (CYT0387), ilginatinib maleate (NS-018), pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), INCB052793, and XL019.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of a LOXL protein, e.g., LOXL1 (NCBI Gene ID: 4016), LOXL2 (NCBI Gene ID: 4017), LOXL3 (NCBI Gene ID: 84695), LOXL4 (NCBI Gene ID: 84171), and/or LOX (NCBI Gene ID: 4015).
• LOXL2 inhibitors include the antibodies described in WO 2009017833 (Arresto Biosciences), WO 2009035791 (Arresto Biosciences), and WO 2011097513 (Gilead Biologics).
• MMP Matrix Metalloprotease
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of a matrix metallopeptidase (MMP), e.g., an inhibitor of MMP1 (NCBI Gene ID: 4312), MMP2 (NCBI Gene ID: 4313), MMP3 (NCBI Gene ID: 4314), MMP7 (NCBI Gene ID: 4316), MMP8 (NCBI Gene ID: 4317), MMP9 (NCBI Gene ID: 4318); MMP10 (NCBI Gene ID: 4319); MMP11 (NCBI Gene ID: 4320); MMP12 (NCBI Gene ID: 4321), MMP13 (NCBI Gene ID: 4322), MMP14 (NCBI Gene ID: 4323), MMP15 (NCMP1) (NC
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of KRAS proto-oncogene, GTPase (KRAS; a.k.a., NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2; NCBI Gene ID: 3845); NRAS proto-oncogene, GTPase (NRAS; a.k.a., NS6; CMNS; NC
• the Ras inhibitors can inhibit Ras at either the polynucleotide (e.g., transcriptional inhibitor) or polypeptide (e.g., GTPase enzyme inhibitor) level.
• the inhibitors target one or more proteins in the Ras pathway, e.g., inhibit one or more of EGFR, Ras, Raf (A-Raf, B-Raf, C-Raf), MEK (MEK1, MEK2), ERK, PI3K, AKT and mTOR.
• K-Ras inhibitors that can be co-administered include sotorasib (AMG-510), COTI-219, ARS-3248, WDB-178, BI-3406, BI-1701963, SML-8-73-1 (G12C), adagrasib (MRTX-849), ARS-1620 (G12C), SML-8-73-1 (G12C), Compound 3144 (G12D), Kobe0065/2602 (Ras GTP), RT11, MRTX-849 (G12C) and K-Ras(G12D)-selective inhibitory peptides, including KRpep-2 and KRpep-2d.
• sotorasib AMG-510
• COTI-219 COTI-219
• ARS-3248 cort alpha-2
• WDB-178 BI-3406, BI-1701963
• SML-8-73-1 G12C
• MRTX-849 adagrasib
• ARS-1620
• Illustrative KRAS mRNA inhibitors include anti-KRAS U1 adaptor, AZD-4785, siG12D-LODERTM, and siG12D exosomes.
• Illustrative MEK inhibitors that can be co-administered include binimetinib, cobimetinib, PD-0325901, pimasertib, RG-7304, selumetinib, trametinib, and those described below and herein.
• Illustrative Raf dimer inhibitors that can be co-administered include BGB-283, HM-95573, LXH-254, LY-3009120, RG7304 and TAK-580.
• Illustrative ERK inhibitors that can be co-administered include LTT-462, LY-3214996, MK-8353, ravoxertinib and ulixertinib.
• Illustrative Ras GTPase inhibitors that can be co-administered include rigosertib.
• Illustrative PI3K inhibitors that can be co-administered include idelalisib (Zydelig®), alpelisib, buparlisib, pictilisib, inavolisib (RG6114), ASN-003.
• Illustrative AKT inhibitors that can be co-administered include capivasertib and GSK2141795.
• Illustrative PI3K/mTOR inhibitors that can be co-administered include dactolisib, omipalisib, voxtalisib.
• gedatolisib GSK2141795, GSK-2126458, inavolisib (RG6114), sapanisertib, ME-344, sirolimus (oral nano-amorphous formulation, cancer), racemetyrosine (TYME-88 (mTOR/cytochrome P450 3A4)), temsirolimus (TORISEL®, CCI-779), CC-115, onatasertib (CC-223), SF-1126, and PQR-309 (bimiralisib).
• Ras-driven cancers having CDKN2A mutations can be inhibited by co-administration of the MEK inhibitor selumetinib and the CDK4/6 inhibitor palbociclib.
• MEK inhibitor selumetinib and CDK4/6 inhibitor palbociclib See, e.g., Zhou, et al., Cancer Lett. 2017 Nov. 1; 408:130-137.
• K-RAS and mutant N-RAS can be reduced by the irreversible ERBB1/2/4 inhibitor neratinib. See, e.g., Booth, et al., Cancer Biol Ther. 2018 Feb. 1; 19(2):132-137.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of mitogen-activated protein kinase kinase 7 (MAP2K7, JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7, SAPKK-4, SAPKK4; NCBI Gene ID: 5609).
• mitogen-activated protein kinase kinase 7 mitogen-activated protein kinase kinase 7
• MEK inhibitors include antroquinonol, binimetinib, cobimetinib (GDC-0973, XL-518), MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212), uprosertib+trametinib, PD-0325901, pimasertib, LTT462, AS703988, CC-90003, and refametinib.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an inhibitor of a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, e.g., phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-alpha, p110-alpha; NCBI Gene ID: 5290); phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB, P110BETA, PI
• the PI3K inhibitor is a pan-PI3K inhibitor.
• PI3K inhibitors include ACP-319, AEZA-129, AMG-319, AS252424, AZD8186, BAY 10824391, BEZ235, buparlisib (BKM120), BYL719 (alpelisib), CH5132799, copanlisib (BAY 80-6946), duvelisib, GDC-0032, GDC-0077, GDC-0941, GDC-0980, GSK2636771, GSK2269557, idelalisib (Zydelig®), INCB50465, IPI-145, IPI-443, IPI-549, KAR4141, LY294002, LY3023414, MLN1117, OXY111A, PA799, PX-866, RG7604, rigosertib, RP5090, RP6530, SRX3177, t
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of spleen associated tyrosine kinase (SYK, p72-Syk, NCBI Gene ID: 6850).
• SYK spleen associated tyrosine kinase
• SYK inhibitors include 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib (R788), HMPL-523, NVP-QAB 205 AA, R112, R343, tamatinib (R406), gusacitinib (ASN-002), and those described in U.S. Pat. No. 8,450,321 (Gilead Connecticut) and US20150175616.
• TLR Toll-Like Receptor
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof is administered with an agonist of a toll-like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and/or TLR10 (NCBI Gene ID: 81793).
• TLR toll-like receptor
• Example TLR7 agonists that can be co-administered include DS-0509, GS-9620 (vesatolimod), vesatolimod analogs, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7795, BDB-001, DSP-0509, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014056953 (Janssen), WO2014076221 (Janssen), WO2014128189 (Janssen), US201403
• TLR7/TLR8 agonist that can be co-administered is NKTR-262.
• Example TLR8 agonists that can be co-administered include E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M-052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118
• Example TLR9 agonists that can be co-administered include AST-008, CMP-001, IMO-2055, IMO-2125, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod (MGN-1703), CYT-003, CYT-003-QbG10 and PUL-042.
• TLR3 agonist include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1.
• TKIs Tyrosine-Kinase Inhibitors
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a tyrosine kinase inhibitor (TKI).
• TKIs may target epidermal growth factor receptors (EGFRs) and receptors for fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF).
• TKIs include without limitation afatinib, ARQ-087 (derazantinib), asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713, icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib, lenvatinib, midostaurin, nintedanib, ODM-203, osimertinib (AZD-9291), ponatinib, poziotinib, quizartinib, radotinib,
• Exemplary EGFR targeting agents include neratinib, tucatinib (ONT-380), tesevatinib, mobocertinib (TAK-788), DZD-9008, varlitinib, abivertinib (ACEA-0010), EGF816 (nazartinib), olmutinib (BI-1482694), osimertinib (AZD-9291), AMG-596 (EGFRvIII/CD3), lifirafenib (BGB-283), vectibix, lazertinib (LECLAZA®), and compounds disclosed in Booth, et al., Cancer Biol Ther. 2018 Feb.
• Antibodies targeting EGFR include without limitation modotuximab, cetuximab sarotalocan (RM-1929), seribantumab, necitumumab, depatuxizumab mafodotin (ABT-414), tomuzotuximab, depatuxizumab (ABT-806), and cetuximab.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a chemotherapeutic agent or anti-neoplastic agent.
• chemotherapeutic agent or “chemotherapeutic” (or “chemotherapy” in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (e.g., non-peptidic) chemical compound useful in the treatment of cancer.
• chemotherapeutic agents include but not limited to: alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodepa, carboquone, meturedepa, and uredepa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimemylolomelamine; acetogenins, e.g., bullatacin and bullatacinone; a camptothecin, including synthetic analog topotecan; bryostatin, callystatin; CC-1065, including its adozelesin, carzelesin, and bizelesin synthetic analogs; cryptophycins, particularly cryptophycin 1 and cryptophycin 8; dolastatin;
• chemotherapeutic agent are anti-hormonal agents such as anti-estrogens and selective estrogen receptor modulators (SERMs), inhibitors of the enzyme aromatase, anti-androgens, and pharmaceutically acceptable salts, acids or derivatives of any of the above that act to regulate or inhibit hormone action on tumors.
• SERMs selective estrogen receptor modulators
• anti-estrogens and SERMs examples include tamoxifen (including NOLVADEXTM), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (FARESTON®).
• Inhibitors of the enzyme aromatase regulate estrogen production in the adrenal glands include 4(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGACE®), exemestane, formestane, fadrozole, vorozole (RIVISOR®), letrozole (FEMARA®), and anastrozole (ARIMIDEX®).
• anti-androgens examples include apalutamide, abiraterone, enzalutamide, flutamide, galeterone, nilutamide, bicalutamide, leuprolide, goserelin, ODM-201, APC-100, ODM-204, enobosarm (GTX-024), darolutamide, and IONIS-AR-2.5Rx (antisense).
• An example progesterone receptor antagonist includes onapristone. Additional progesterone targeting agents include TRI-CYCLEN LO (norethindrone+ethinyl estradiol), norgestimate+ethinylestradiol (Tri-Cyclen) and levonorgestrel.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-angiogenic agent.
• Anti-angiogenic agents that can be co-administered include retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN®, ENDOSTATIN®, regorafenib, necuparanib, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism including proline analogs such as 1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I-3,4-dehydroproline, thi
• anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF, and Ang-1/Ang-2.
• anti-VEGFA antibodies that can be co-administered include bevacizumab, vanucizumab, faricimab, dilpacimab (ABT-165; DLL4/VEGF), ornavicixizumab (OMP-305B83; DLL4/VEGF).
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-fibrotic agent.
• Anti-fibrotic agents that can be co-administered include the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in U.S. Pat. No. 4,965,288 relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen and U.S.
• Pat. No. 4,997,854 relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are described in U.S. Pat. No. 4,943,593 relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine, U.S. Pat. Nos. 5,021,456, 5,059,714, 5,120,764, 5,182,297, 5,252,608 relating to 2-(1-naphthyloxymemyl)-3-fluoroallylamine, and US 20040248871, which are herein incorporated by reference.
• Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives; semicarbazide and urea derivatives; aminonitriles such as BAPN or 2-nitroethylamine; unsaturated or saturated haloamines such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, and p-halobenzylamines; and selenohomocysteine lactone.
• primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product
• anti-fibrotic agents are copper chelating agents penetrating or not penetrating the cells.
• Exemplary compounds include indirect inhibitors which block the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases.
• Examples include the thiolamines, particularly D-penicillamine, and its analogs such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio) butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate, and sodium-4-mercaptobutanesulphinate trihydrate.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-inflammatory agent.
• Example anti-inflammatory agents include without limitation inhibitors of one or more of arginase (ARG1 (NCBI Gene ID: 383), ARG2 (NCBI Gene ID: 384)), carbonic anhydrase (CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632)), prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 57
• inhibitors of prostaglandin-endoperoxide synthase 1 include mofezolac, GLY-230, and TRK-700.
• inhibitors of prostaglandin-endoperoxide synthase 2 include diclofenac, meloxicam, parecoxib, etoricoxib, AP-101, celecoxib, AXS-06, diclofenac potassium, DRGT-46, AAT-076, meisuoshuli, lumiracoxib, meloxicam, valdecoxib, zaltoprofen, nimesulide, anitrazafen, apricoxib, cimicoxib, deracoxib, flumizole, firocoxib, mavacoxib, NS-398, pamicogrel, parecoxib, robenacoxib, rofecoxib, rutecarpine, tilmacoxib, and zaltoprofen.
• Examples of dual COX1/COX2 inhibitors that can be co-administered include HP-5000, lornoxicam, ketorolac tromethamine, bromfenac sodium, ATB-346, HP-5000.
• Examples of dual COX-2/carbonic anhydrase (CA) inhibitors that can be co-administered include polmacoxib and imrecoxib.
• inhibitors of secreted phospholipase A2, prostaglandin E synthase include LY3023703, GRC 27864, and compounds described in WO2015158204, WO2013024898, WO2006063466, WO2007059610, WO2007124589, WO2010100249, WO2010034796, WO2010034797, WO2012022793, WO2012076673, WO2012076672, WO2010034798, WO2010034799, WO2012022792, WO2009103778, WO2011048004, WO2012087771, WO2012161965, WO2013118071, WO2013072825, WO2014167444, WO2009138376, WO2011023812, WO2012110860, WO2013153535, WO2009130242, WO2009146696, WO2013186692, WO20150596
• Metformin has further been found to repress the COX2/PGE2/STAT3 axis, and can be co-administered. See, e.g., Tong, et al., Cancer Lett . (2017) 389:23-32; and Liu, et al., Oncotarget . (2016) 7(19):28235-46.
• inhibitors of carbonic anhydrase include acetazolamide, methazolamide, dorzolamide, zonisamide, brinzolamide and dichlorphenamide.
• a dual COX-2/CA1/CA2 inhibitor that can be co-administered include acetazolamide, methazolamide, dorzolamide, zonisamide, brinzolamide and dichlorphenamide.
• inhibitors of arachidonate 5-lipoxygenase include meclofenamate sodium, zileuton.
• inhibitors of soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053) that can be co-administered include compounds described in WO2015148954.
• Dual inhibitors of COX-2/SEH that can be co-administered include compounds described in WO2012082647.
• Dual inhibitors of SEH and fatty acid amide hydrolase (FAAH; NCBI Gene ID: 2166) that can be co-administered include compounds described in WO2017160861.
• inhibitors of mitogen-activated protein kinase kinase kinase 8 that can be co-administered include GS-4875, GS-5290, BHM-078 and those described in WO2006124944, WO2006124692, WO2014064215, WO2018005435, Teli, et al., J Enzyme Inhib Med Chem . (2012) 27(4):558-70; Gangwall, et al., Curr Top Med Chem . (2013) 13(9):1015-35; Wu, et al., Bioorg Med Chem Lett .
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an agent that promotes or increases tumor oxygenation or reoxygenation, or prevents or reduces tumor hypoxia.
• Illustrative agents that can be co-administered include, e.g., Hypoxia inducible factor-1 alpha (HIF-1 ⁇ ) inhibitors, such as PT-2977, PT-2385; VEGF inhibitors, such as bevasizumab, IMC-3C5, GNR-011, tanibirumab, LYN-00101, ABT-165; and/or an oxygen carrier protein (e.g., a heme nitric oxide and/or oxygen binding protein (HNOX)), such as OMX-302 and HNOX proteins described in WO2007137767, WO2007139791, WO2014107171, and WO2016149562.
• HNF-1 ⁇ Hypoxia inducible factor-1 alpha
• HIF-1 ⁇ Hypoxia inducible factor-1 alpha
• VEGF inhibitors such as bevasizumab, IMC-3C5, GNR-011, tanibirumab, LYN-00101, ABT-165
• an oxygen carrier protein
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with an immunotherapeutic agent.
• the immunotherapeutic agent is an antibody.
• Example immunotherapeutic agents that can be co-administered include abagovomab, AB308, ABP-980, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, atezolizumab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, camidanlurnab, cantuzumab, catumaxomab, CC49, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, dacetuzumab, dalotuzumab, daratumumab, detumomab, dinutuximab, domvanalima
• Rituximab can be used for treating indolent B-cell cancers, including marginal-zone lymphoma, WM, CLL, and small lymphocytic lymphoma. A combination of rituximab and chemotherapy agents is especially effective.
• the exemplified therapeutic antibodies can be further labeled or combined with a radioisotope particle such as indium-111, yttrium-90 (90Y-clivatuzumab), or iodine-131.
• a radioisotope particle such as indium-111, yttrium-90 (90Y-clivatuzumab), or iodine-131.
• the immunotherapeutic agent that can be co-administered is an antibody-drug conjugate (ADC).
• ADCs that can be co-administered include without limitation drug-conjugated antibodies, fragments thereof, or antibody mimetics targeting the proteins or antigens listed above and herein.
• Example ADCs that can be co-administered include gemtuzumab, brentuximab, belantamab (e.g., belantamab mafodotin), camidankumab (e.g.
• trastuzumab e.g., trastuzumab deruxtecan; trasuzumab emtansine
• inotuzumab glembatumumab, anetumab
• mirvetuximab e.g., mirvetuximab soravtansine
• depatuxizumab vadastuximab
• labetuzumab ladiratuzumab (e.g., ladiratuzumab vedotin)
• loncastuximab e.g., loncastuximab tesirine
• sacituzumab e.g., sacituzumab govitecan
• datopotamab e.g., datopotamab deruxtecan; DS-1062; Dato-DXd
• patritumab e.g., patritumab deruxtecan
• ADCs that can be co-administered are described, e.g., in Lambert, et al., Adv Ther (2017) 34:1015-1035 and in de Goeij, Current Opinion in Immunology (2016) 40:14-23.
• Illustrative therapeutic agents that can be conjugated to the drug-conjugated antibodies, fragments thereof, or antibody mimetics include without limitation monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), a calicheamicin, ansamitocin, maytansine or an analog thereof (e.g., mertansine/emtansine (DM1), ravtansine/soravtansine (DM4)), an anthracyline (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin), pyrrolobenzodiazepine (PBD) DNA cross-linking agent SC-DR002 (D6.5), duocarmycin, a microtubule inhibitors (MTI) (e.g., a taxane, a vinca alkaloid, an epothilone), a pyrrolobenzodiazepine
• MMI microtubule inhibitors
• the therapeutic agent conjugated to the drug-conjugated antibody is a topoisomerase I inhibitor (e.g., a camptothecin analog, such as irinotecan or its active metabolite SN38).
• the therapeutic agents e.g., anticancer or antineoplastic agents
• the conjugated immune checkpoint inhibitor is a conjugated small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1) or CTLA4.
• the conjugated small molecule inhibitor of CD274 or PDCD1 is selected from the group consisting of GS-4224, GS-4416, INCB086550 and MAX10181.
• the conjugated small molecule inhibitor of CTLA4 comprises BPI-002.
• the ADCs that can be co-administered include an antibody targeting tumor-associated calcium signal transducer 2 (TROP-2; TACSTD2; EGP-1; NCBI Gene ID: 4070).
• Illustrative anti-TROP-2 antibodies include without limitation TROP2-XPAT (Amunix), BAT-8003 (Bio-Thera Solutions), TROP-2-IR700 (Chiome Bioscience), datopotamab deruxtecan (Daiichi Sankyo, AstraZeneca), GQ-1003 (Genequantum Healthcare, Samsung BioLogics), DAC-002 (Hangzhou DAC Biotech, Shanghai Junshi Biosciences), sacituzumab govitecan (Gilead Sciences), E1-3s (Immunomedics/Gilead, IBC Pharmaceuticals), TROP2-TRACTr (Janux Therapeutics), LIV-2008 (LivTech/Chiome, Yakult Honsha, Shanghai Henlius BioTech), LIV-2008b (LivTech
• the anti-Trop-2 antibody is selected from hRS7, Trop-2-XPAT, and BAT-8003.
• the anti-Trop-2 antibody is hRS7.
• hRS7 is as disclosed in U.S. Pat. Nos. 7,238,785; 7,517,964 and 8,084,583, which are incorporated herein by reference.
• the antibody-drug conjugate comprises an anti-Trop-2 antibody and an anticancer agent linked by a linker.
• the linker includes the linkers disclosed in U.S. Pat. No. 7,999,083.
• the linker is CL2A.
• the drug moiety of antibody-drug conjugate is a chemotherapeutic agent.
• the chemotherapeutic agent is selected from doxorubcin (DOX), epirubicin, morpholinodoxorubicin (morpholino-DOX), cyanomorpholino-doxorubicin (cyanomorpholinoDOX), 2-pyrrolino-doxorubicin (2-PDOX), CPT, 10-hydroxy camptothecin, SN-38, topotecan, lurtotecan, 9-aminocamptothecin, 9-nitrocamptothecin, taxanes, geldanamycin, ansamycins, and epothilones.
• the chemotherapeutic moiety is SN-38.
• the antibody and/or fusion protein provided herein is administered with sacituzumab govitecan.
• the ADCs that can be co-administered include an antibody targeting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1; CD66a; NCBI Gene ID: 634).
• CEACAM1 an antibody targeting carcinoembryonic antigen-related cell adhesion molecule 1
• the CEACAM1 antibody is hMN-14 (e.g., as described in WO1996011013).
• CEACAM1-ADC is as described in WO2010093395 (anti-CEACAM-1-CL2A-SN38).
• the antibody and/or fusion protein provided herein is administered with the CEACAM1-ADC IMMU-130.
• the ADCs that can be co-administered include an antibody targeting MHC class II cell surface receptor encoded by the human leukocyte antigen complex (HLA-DR).
• HLA-DR antibody is hL243 (e.g., as described in WO2006094192).
• HLA-DR-ADC is as described in WO2010093395 (anti-HLA-DR-CL2A-SN38).
• the antibody and/or fusion protein provided herein is administered with the HLA-DR-ADC IMMU-140.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with a cancer gene therapy and cell therapy.
• Cancer gene therapies and cell therapies include the insertion of a normal gene into cancer cells to replace a mutated or altered gene; genetic modification to silence a mutated gene; genetic approaches to directly kill the cancer cells; including the infusion of immune cells designed to replace most of the patient's own immune system to enhance the immune response to cancer cells, or activate the patient's own immune system (T cells or Natural Killer cells) to kill cancer cells, or find and kill the cancer cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against cancer.
• a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe-1), (IIe-2), (IIf), (IIg), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more cellular therapies.
• Illustrative cellular therapies include without limitation co-administration of one or more of a population of natural killer (NK) cells, NK-T cells, T cells, cytokine-induced killer (CIK) cells, macrophage (MAC) cells, tumor infiltrating lymphocytes (TILs) and/or dendritic cells (DCs).
• the cellular therapy entails a T cell therapy, e.g., co-administering a population of alpha/beta TCR T cells, gamma/delta TCR T cells, regulatory T (Treg) cells and/or TRuCTM T cells.
• the cellular therapy entails a NK cell therapy, e.g., co-administering NK-92 cells.
• a cellular therapy can entail the co-administration of cells that are autologous, syngeneic or allogeneic to the subject.
• the cellular therapy entails co-administering cells comprising chimeric antigen receptors (CARs).
• CARs chimeric antigen receptors
• a population of immune effector cells engineered to express a CAR, wherein the CAR comprises a tumor antigen-binding domain.
• T cell therapies the T cell receptors (TCRs) are engineered to target tumor derived peptides presented on the surface of tumor cells.
• the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
• the intracellular domain comprises a primary signaling domain, a costimulatory domain, or both of a primary signaling domain and a costimulatory domain.
• the primary signaling domain comprises a functional signaling domain of one or more proteins selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon Rlb), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12.
• a functional signaling domain of one or more proteins selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon Rlb), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12.
• the costimulatory domain comprises a functional domain of one or more proteins selected from the group consisting of CD27, CD28, 4-1BB(CD137), OX40, CD30, CD40, PD-1, ICOS, CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFI), CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, CD103, ITGAL, CD1A (NCBI Gene ID: 909), CD1B (NCBI Gene ID: 910), CD1C (NCBI Gene ID: 911), CD1D (NC) (NCBI
• the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, ICOS (CD278), 4-1BB(CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1A, CD1B, CD1C, CD1D, CD1E, ITGAE, CD103, I
• the TCR or CAR antigen binding domain or the immunotherapeutic agent described herein binds a tumor-associated antigen (TAA).
• TAA tumor-associated antigen
• the tumor-associated antigen is selected from the group consisting of: CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvlll); ganglioside G2 (GD2); ganglioside GD3 ( ⁇ NeuSAc(2-8) ⁇ NeuSAc(2-3) ⁇ DGaip(1-4)bDGIcp(1-1)Cer); ganglioside GM3 ( ⁇ NeuSAc(2-3) ⁇ DGalp(1-4) ⁇ DGlcp(1-1)Cer); TNF receptor superfamily member 17 (TNFRSF17, BCMA); Tn antigen ((Tn Ag) or (GaINAcu-Ser/Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase
• the tumor antigen is selected from CD150, 5T4, ActRIIA, B7, TNF receptor superfamily member 17 (TNFRSF17, BCMA), CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, HER1-HER2 in combination, HER2-HER3 in combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope
• the antigen binding domain binds to an epitope of a target or tumor associated antigen (TAA) presented in a major histocompatibility complex (MHC) molecule.
• TAA tumor associated antigen
• MHC major histocompatibility complex
• the TAA is a cancer testis antigen.
• the cancer testis antigen is selected from the group consisting of acrosin binding protein (ACRBP; CT23, OY-TES-1, SP32; NCBI Gene ID: 84519), alpha fetoprotein (AFP; AFPD, FETA, HPAFP; NCBI Gene ID: 174); A-kinase anchoring protein 4 (AKAP4; AKAP 82, AKAP-4, AKAP82, CT99, FSC1, HI, PRKA4, hAKAP82, p82; NCBI Gene ID: 8852), ATPase family AAA domain containing 2 (ATAD2; ANCCA, CT137, PR02000; NCBI Gene ID: 29028), kinetochore scaffold 1 (KNL1; AF15Q14, CASC5, CT29, D40, MCPH4, PPP1R55, Spc7, hKNL-1, hSpc105; NCBI Gene ID: 57082), centrosomal protein 55 (CEP55; C10
• T cell receptors TCRs
• MHC major histocompatibility complex
• TCRs and TCR-like antibodies that bind to an epitope of NY-ESO-1 presented in an MHC are described, e.g., in Stewart-Jones, et al., Proc Natl Acad Sci USA. 2009 Apr. 7; 106(14):5784-8; WO2005113595, WO2006031221, WO2010106431, WO2016177339, WO2016210365, WO2017044661, WO2017076308, WO2017109496, WO2018132739, WO2019084538, WO2019162043, WO2020086158 and WO2020086647.
• TCRs and TCR-like antibodies that bind to an epitope of PRAME presented in an MHC are described, e.g., in WO2011062634, WO2016142783, WO2016191246, WO2018172533, WO2018234319 and WO2019109821.
• TCRs and TCR-like antibodies that bind to an epitope of a MAGE variant presented in an MHC are described, e.g., in WO2007032255, WO2012054825, WO2013039889, WO2013041865, WO2014118236, WO2016055785, WO2017174822, WO2017174823, WO2017174824, WO2017175006, WO2018097951, WO2018170338, WO2018225732 and WO2019204683.
• Illustrative TCRs and TCR-like antibodies that bind to an epitope of alpha fetoprotein (AFP) presented in an MHC are described, e.g., in WO2015011450.
• TCRs and TCR-like antibodies that bind to an epitope of SSX2 presented in an MHC are described, e.g., in WO2020063488.
• Illustrative TCRs and TCR-like antibodies that bind to an epitope of KK-LC-1 (CT83) presented in an MHC are described, e.g., in WO2017189254.
• cell therapies include: Algenpantucel-L, Sipuleucel-T, (BPX-501) rivogenlecleucel U.S. Pat. No. 9,089,520, WO2016100236, AU-105, ACTR-087, activated allogeneic natural killer cells CNDO-109-AANK, MG-4101, AU-101, BPX-601, FATE-NK100, LFU-835 hematopoietic stem cells, Imilecleucel-T, baltaleucel-T, PNK-007, UCARTCS1, ET-1504, ET-1501, ET-1502, ET-190, CD19-ARTEMIS, ProHema, FT-1050-treated bone marrow stem cell therapy, CD4CARNK-92 cells, CryoStim, AlloStim, lentiviral transduced huCART-meso cells, CART-22 cells, EGFRt/19-28z/4-1BBL CAR T cells, autologous 4H11-28
• the one or more additional co-administered therapeutic agents can be categorized by their mechanism of action, e.g., into the following groups:
• Some chemotherapy agents are suitable for treating lymphoma or leukemia. These agents include aldesleukin, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, Bcl-2 family protein inhibitor ABT-263, beta alethine, BMS-345541, bortezomib (VELCADE®), bortezomib (VELCADE®, PS-341), bryostatin 1, bulsulfan, campath-1H, carboplatin, carfilzomib (Kyprolis®), carmustine, caspofungin acetate, CC-5103, chlorambucil, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), cisplatin, cladribine, clofarabine, curcumin, CVP (cyclo
• radioimmunotherapy wherein a monoclonal antibody is combined with aradioisotope particle, such as indium-111, yttrium-90, and iodine-131.
• aradioisotope particle such as indium-111, yttrium-90, and iodine-131.
• combination therapies include, but are not limited to, iodine-131 tositumomab (BEXXAR®), yttrium-90 ibritumomab tiuxetan (ZEVALIN®), and BEXXAR® with CHOP.
• Therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
• Non-Hodgkin's lymphomas treatments of non-Hodgkin's lymphomas (NHL), especially those of B cell origin, includes using monoclonal antibodies, standard chemotherapy approaches (e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and prednisone), FCM (fludarabine, cyclophosphamide, and mitoxantrone), MCP (Mitoxantrone, Chlorambucil, Prednisolone), all optionally including rituximab (R) and the like), radioimmunotherapy, and combinations thereof, especially integration of an antibody therapy with chemotherapy.
• standard chemotherapy approaches e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and prednis
• unconjugated monoclonal antibodies for the treatment of NHL/B-cell cancers include rituximab, alemtuzumab, human or humanized anti-CD20 antibodies, lumiliximab, anti-TNF-related apoptosis-inducing ligand (anti-TRAIL), bevacizumab, galiximab, epratuzumab, SGN-40, and anti-CD74.
• Examples of experimental antibody agents used in treatment of NHL/B-cell cancers include ofatumumab, ha20, PRO131921, alemtuzumab, galiximab, SGN-40, CHIR-12.12, epratuzumab, lumiliximab, apolizumab, milatuzumab, and bevacizumab.
• NHL/B-cell cancers examples include CHOP, FCM, CVP, MCP, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-FCM, R-CVP, and R MCP.
• radioimmunotherapy for NHL/B-cell cancers examples include yttrium-90 ibritumomab tiuxetan (ZEVALIN®) and iodine-131 tositumomab (BEXXAR®).
• MCL mantle cell lymphoma
• An alternative approach to treating MCL is immunotherapy.
• One immunotherapy uses monoclonal antibodies like rituximab.
• a modified approach to treat MCL is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as iodine-131 tositumomab (BEXXAR®) and yttrium-90 ibritumomab tiuxetan (ZEVALIN®).
• a radioisotope particle such as iodine-131 tositumomab (BEXXAR®) and yttrium-90 ibritumomab tiuxetan (ZEVALIN®).
• BEXXAR® is used in sequential treatment with CHOP.
• MCL multi-densarcoma
• proteasome inhibitors such as bortezomib (VELCADE® or PS-341)
• antiangiogenesis agents such as thalidomide
• Another treatment approach is administering drugs that lead to the degradation of Bcl-2 protein and increase cancer cell sensitivity to chemotherapy, such as oblimersen, in combination with other chemotherapeutic agents.
• a further treatment approach includes administering mTOR inhibitors, which can lead to inhibition of cell growth and even cell death.
• mTOR inhibitors include sirolimus, temsirolimus (TORISEL®, CCI-779), CC-115, CC-223, SF-1126, PQR-309 (bimiralisib), voxtalisib, GSK-2126458, and temsirolimus in combination with RITUXAN®, VELCADE®, or other chemotherapeutic agents.
• Such examples include flavopiridol, palbociclib (PD0332991), R-roscovitine (selicicilib, CYC202), styryl sulphones, obatoclax (GX15-070), TRAIL, Anti-TRAIL death receptors DR4 and DR5 antibodies, temsirolimus (TORISEL®, CCI-779), everolimus (RAD001), BMS-345541, curcumin, SAHA, thalidomide, lenalidomide (REVLIMID®, CC-5013), and geldanamycin (17 AAG).
• Therapeutic agents used to treat Waldenstrom's Macroglobulinemia include aldesleukin, alemtuzumab, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, autologous human tumor-derived HSPPC-96, Bcl-2 family protein inhibitor ABT-263, beta alethine, bortezomib (VELCADE®), bryostatin 1, busulfan, campath-1H, carboplatin, carmustine, caspofungin acetate, CC-5103, cisplatin, clofarabine, cyclophosphamide, cyclosporine, cytarabine, denileukin diftitox, dexamethasone, docetaxel, dolastatin 10, doxorubicin hydrochloride, DT-PACE, enzasta
• Examples of therapeutic procedures used to treat WM include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme techniques, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
• Therapeutic agents used to treat diffuse large B-cell lymphoma include cyclophosphamide, doxorubicin, vincristine, prednisone, anti-CD20 monoclonal antibodies, etoposide, bleomycin, many of the agents listed for WM, and any combination thereof, such as ICE and RICE.
• therapeutic agents used to treat DLBCL include rituximab (Rituxan®), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin®), prednisone, bendamustine, ifosfamide, carboplatin, etoposide, ibrutinib, polatuzumab vedotin piiq, bendamustine, copanlisib, lenalidomide (Revlimid®), dexamethasone, cytarabine, cisplatin, Yescarta®, Kymriah®, Polivy®(polatuzumab vedotin), BR (bendamustine (Treanda®), gemcitabine, oxiplatin, oxaliplatin, tafasitamab, polatuzumab, cyclopho
• therapeutic agents used to treat DLBCL include R-CHOP (rituximab+cyclophosphamide+doxorubicin hydrochloride (hydroxydaunorubicin)+vincristine sulfate (Oncovin®), +prednisone), rituximab+bendamustine, R-ICE (Rituximab+Ifosfamide+Carboplatin+Etoposide), rituximab+lenalomide, R-DHAP (rituximab+dexamethasone+high-dose cytarabine (Ara C)+cisplatin), Polivy®(polatuzumab vedotin)+BR (bendamustine (Treanda®) and rituximab (Rituxan®), R-GemOx (Gemcitabine+oxaliplatin+rituximab), Tafa-Len (ta
• therapeutic agents used to treat DLBCL include tafasitamab, glofitamab, epcoritamab, Lonca-T (loncastuximab tesirine), Debio-1562, polatuzumab, Yescarta, JCAR017, ADCT-402, brentuximab vedotin, MT-3724, odronextamab, Auto-03, Allo-501A, or TAK-007.
• Therapeutic agents used to treat chronic lymphocytic leukemia include chlorambucil, cyclophosphamide, fludarabine, pentostatin, cladribine, doxorubicin, vincristine, prednisone, prednisolone, alemtuzumab, many of the agents listed for WM, and combination chemotherapy and chemoimmunotherapy, including the following common combination regimens: CVP, R-CVP, ICE, R-ICE, FCR, and FR.
• Therapeutic agents used to treat HR MDS include azacitidine (Vidaza®), decitabine (Dacogen®), lenalidomide (Revlimid®), cytarabine, idarubicin, daunorubicin, and combinations thereof. In some embodiments combinations include cytarabine+daunorubicin and cytarabine+idarubicin. In some embodiments therapeutic agents used to treat HR MDS include pevonedistat, venetoclax, sabatolimab, guadecitabine, rigosertib, ivosidenib, enasidenib, selinexor, BGB324, DSP-7888, or SNS-301.
• Therapeutic agents used to treat LR MDS include lenalidomide, azacytidine, and combinations thereof.
• therapeutic agents used to treat LR MDS include roxadustat, luspatercept, imetelstat, LB-100, or rigosertib.
• AML Acute Myeloid Leukemia
• Therapautic agents used to treat AML include cytarabine, idarubicin, daunorubicin, midostaurin (Rydapt®), venetoclax, azacitidine, ivasidenib, gilteritinib, enasidenib, low-dose cytarabine (LoDAC), mitoxantrone, fludarabine, granulocyte-colony stimulating factor, idarubicin, gilteritinib (Xospata®), enasidenib (Idhifa®), ivosidenib (Tibsovo®), decitabine (Dacogen®), mitoxantrone, etoposide, Gemtuzumab ozogamicin (Mylotarg®), glasdegib (Daurismo®), and combinations thereof.
• cytarabine idarubicin, daunorubicin, midostaurin (Rydapt
• therapeutic agents used to treat AML include FLAG-Ida (fludarabine, cytarabine (Ara-C), granulocyte-colony stimulating factor (G-CSF) and idarubicin), cytarabine+idarubicin, cytarabine+daunorubicin+midostaurin, venetoclax+azacitidine, cytarabine+daunorubicin, or MEC (mitoxantrone, etoposide, and cytarabine).
• therapeutic agents used to treat AML include pevonedistat, venetoclax, sabatolimab, eprenetapopt, or lemzoparlimab.
• MM Multiple Myeloma
• Therapeutic agents used to treat MM include lenalidomide, bortezomib, dexamethasone, daratumumab (Darzalex®), pomalidomide, Cyclophosphamide, Carfilzomib (Kyprolis®), Elotuzumab (Empliciti), and combinations thereof.
• therapeutic agents used to treat MM include RVS (lenalidomide+bortezomib+dexamethasone), RevDex (lenalidomide plus dexamethasone), CYBORD (Cyclophosphamide+Bortezomib+Dexamethasone), Vel/Dex (bortezomib plus dexamethasone), or PomDex (Pomalidomide+low-dose dexamethasone).
• therapeutic agents used to treat MM include JCARH125, TAK-573, belantamab-m, ide-cel (CAR-T).
• Therapeutic agents used to treat breast cancer include albumin-bound paclitaxel, anastrozole, atezolizumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin, everolimus, exemestane, fluorouracil, fulvestrant, gemcitabine, Ixabepilone, lapatinib, letrozole, methotrexate, mitoxantrone, paclitaxel, pegylated liposomal doxorubicin, pertuzumab, tamoxifen, toremifene, trastuzumab, vinorelbine, and any combinations thereof.
• therapeutic agents used to treat breast cancer include trastuzumab (Herceptin ⁇ ), pertuzumab (Perjeta ⁇ ), docetaxel, carboplatin, palbociclib (Ibrance ⁇ ), letrozole, trastuzumab emtansine (Kadcyla ⁇ ), fulvestrant (Faslodex ⁇ ), olaparib (Lynparza ⁇ ), eribulin, tucatinib, capecitabine, lapatinib, everolimus (Afinitor ⁇ ), exemestane, eribulin mesylate (Halaven®), and combinations thereof.
• therapeutic agents used to treat breast cancer include trastuzumab+pertuzumab+docetaxel, trastuzumab+pertuzumab+docetaxel+carboplatin, palbociclib+letrozole, tucatinib+capecitabine, lapatinib+capecitabine, palbociclib+fulvestrant, or everolimus+exemestane.
• therapeutic agents used to treat breast cancer include trastuzumab deruxtecan (Enhertu ⁇ ), datopotamab deruxtecan (DS-1062), enfortumab vedotin (Padcev®), balixafortide, elacestrant, or a combination thereof.
• therapeutic agents used to treat breast cancer include balixafortide+eribulin.
• TNBC Triple Negative Breast Cancer
• Therapeutic agents used to treat TNBC include atezolizumab, cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil, paclitaxel, and combinations thereof.
• therapeutic agents used to treat TNBC include olaparib (Lynparza®), atezolizumab (Tecentriq®), paclitaxel (Abraxane®), eribulin, bevacizumab (Avastin®), carboplatin, gemcitabine, eribulin mesylate (Halaven®), sacituzumab govitecan (Trodelvy®), pembrolizumab (Keytruda®), cisplatin, doxorubicin, epirubicin, or a combination thereof.
• therapeutic agents to treat TNBC include atezolizumab+paclitaxel, bevacizumab+paclitaxel, carboplatin+paclitaxel, carboplatin+gemcitabine, or paclitaxel+gemcitabine.
• therapeutic agents used to treat TNBC include eryaspase, capivasertib, alpelisib, rucaparib+nivolumab, atezolumab+paclitaxel+gemcitabine+capecitabine+carboplatin, ipatasertib+paclitaxel, ladiratuzumab vedotin+pembrolimab, durvalumab+DS-8201a, trilaciclib+gemcitabine+carboplatin.
• therapeutic agents used to treat TNBC include trastuzumab deruxtecan (Enhertu®), datopotamab deruxtecan (DS-1062), enfortumab vedotin (Padcev®), balixafortide, adagloxad simolenin, nelipepimut-s (NeuVax®), nivolumab (Opdivo®), rucaparib, toripalimab (Tuoyi®), camrelizumab, capivasertib, durvalumab (Imfinzi®), and combinations thereof.
• therapeutic agents use to treat TNBC include nivolumab+rucaparib, bevacizumab (Avastin®)+chemotherapy, toripalimab+paclitaxel, toripalimab+albumin-bound paclitaxel, camrelizumab+chemotherapy, pembrolizumab+chemotherapy, balixafortide+eribulin, durvalumab+trastuzumab deruxtecan, durvalumab+paclitaxel, or capivasertib+paclitaxel.
• bevacizumab Avastin®
• toripalimab+paclitaxel toripalimab+albumin-bound paclitaxel
• camrelizumab+chemotherapy pembrolizumab+chemotherapy
• balixafortide+eribulin durvalumab+trastuzumab deruxtecan
• durvalumab+paclitaxel or capivasertib
• Therapeutic agents used to treat bladder cancer include datopotamab deruxtecan (DS-1062), trastuzumab deruxtecan (Enhertu ⁇ ), erdafitinib, eganelisib, lenvatinib, bempegaldesleukin (NKTR-214), or a combination thereof.
• therapeutic agents used to treat bladder cancer include eganelisib+nivolumab, pembrolizumab (Keytruda ⁇ )+enfortumab vedotin (Padcev ⁇ ), nivolumab+ipilimumab, duravalumab+tremelimumab, lenvatinib+pembrolizumab, enfortumab vedotin (Padcev ⁇ )+pembrolizumab, and bempegaldesleukin+nivolumab.
• Therapeutic agents used to treat CRC include bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, and any combinations thereof.
• therapeutic agents used to treat CRC include bevacizumab (Avastin ⁇ ), leucovorin, 5-FU, oxaliplatin (FOLFOX), pembrolizumab (Keytruda ⁇ ), FOLFIRI, regorafenib (Stivarga®), aflibercept (Zaltrap®), cetuximab (Erbitux®), Lonsurf (Orcantas®), XELOX, FOLFOXIRI, or a combination thereof.
• therapeutic agents used to treat CRC include bevacizumab+leucovorin+5-FU+oxaliplatin (FOLFOX), bevacizumab+FOLFIRI, bevacizumab+FOLFOX, aflibercept+FOLFIRI, cetuximab+FOLFIRI, bevacizumab+XELOX, and bevacizumab+FOLFOXIRI.
• FOLFOX bevacizumab+leucovorin+5-FU+oxaliplatin
• bevacizumab+FOLFIRI bevacizumab+FOLFOX
• aflibercept+FOLFIRI cetuximab+FOLFIRI
• bevacizumab+XELOX bevacizumab+FOLFOXIRI.
• therapeutic agents used to treat CRC include binimetinib+encorafenib+cetuximab, trametinib+dabrafenib+panitumumab, trastuzumab+pertuzumab, napabucasin+FOLFIRI+bevacizumab, nivolumab+ipilimumab.
• Therapeutic agents used to treat esophageal and esophagogastric junction cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, irinotecan, leucovorin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.
• therapeutic agents used to treat gastroesophageal junction cancer (GEJ) include herceptin, cisplatin, 5-FU, ramicurimab, or paclitaxel.
• therapeutic agents used to treat GEJ cancer include ALX-148, AO-176, or IBI-188.
• Therapeutic agents used to treat gastric cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, Irinotecan, leucovorin, mitomycin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.
• Therapeutic agents used to treat head & neck cancer include afatinib, bleomycin, capecitabine, carboplatin, cetuximab, cisplatin, docetaxel, fluorouracil, gemcitabine, hydroxyurea, methotrexate, nivolumab, paclitaxel, pembrolizumab, vinorelbine, and any combinations thereof.
• Therapeutic agents used to treat head and neck squamous cell carcinoma include pembrolizumab, carboplatin, 5-FU, docetaxel, cetuximab (Erbitux ⁇ ), cisplatin, nivolumab (Opdivo ⁇ ), and combinations thereof.
• therapeutic agents used to treat HNSCC include pembrolizumab+carboplatin+5-FU, cetuximab+cisplatin+5-FU, cetuximab+carboplatin+5-FU, cisplatin+5-FU, and carboplatin+5-FU.
• therapeutic agents used to treat HNSCC include durvalumab, durvalumab+tremelimumab, nivolumab+ipilimumab, rovaluecel, pembrolizumab, pembrolizumab+epacadostat, GSK3359609+pembrolizumab, lenvatinib+pembrolizumab, retifanlimab, retifanlimab+enobituzumab, ADU-S100+pembrolizumab, epacadostat+nivolumab+ipilimumab/lirilumab.
• Therapeutic agents used to treat non-small cell lung cancer include afatinib, albumin-bound paclitaxel, alectinib, atezolizumab, bevacizumab, bevacizumab, cabozantinib, carboplatin, cisplatin, crizotinib, dabrafenib, docetaxel, erlotinib, etoposide, gemcitabine, nivolumab, paclitaxel, pembrolizumab, pemetrexed, ramucirumab, trametinib, trastuzumab, vandetanib, vemurafenib, vinblastine, vinorelbine, and any combinations thereof.
• NSCLC non-small cell lung cancer
• therapeutic agents used to treat NSCLC include alectinib (Alecensa®), dabrafenib (Tafinlar®), trametinib (Mekinist®), osimertinib (Tagrisso®), entrectinib (Tarceva®), crizotinib (Xalkori®), pembrolizumab (Keytruda®), carboplatin, pemetrexed (Alimta®), nab-paclitaxel (Abraxane®), ramucirumab (Cyramza®), docetaxel, bevacizumab (Avastin®), brigatinib, gemcitabine, cisplatin, afatinib (Gilotrif®), nivolumab (Opdivo®), gefitinib (Iressa®), and combinations thereof.
• alectinib Alecensa®
• dabrafenib
• therapeutic agents used to treat NSCLC include dabrafenib+trametinib, pembrolizumab+carboplatin+pemetrexed, pembrolizumab+carboplatin+nab-paclitaxel, ramucirumab+docetaxel, bevacizumab+carboplatin+pemetrexed, pembrolizumab+pemetrexed+carboplatin, cisplatin+pemetrexed, bevacizumab+carboplatin+nab-paclitaxel, cisplatin+gemcitabine, nivolumab+docetaxel, carboplatin+pemetrexed, carboplatin+nab-paclitaxel, or pemetrexed+cisplatin+carboplatin.
• therapeutic agents used to NSCLC include datopotamab deruxtecan (DS-1062), trastuzumab deruxtecan (Enhertu ⁇ ), enfortumab vedotin (Padcev ⁇ ), durvalumab, canakinumab, cemiplimab, nogapendekin alfa, avelumab, tiragolumab, domvanalimab, vibostolimab, ociperlimab, or a combination thereof.
• therapeutic agents used to treat NSCLC include datopotamab deruxtecan+pembrolizumab, datopotamab deruxtecan+durvalumab, durvalumab+tremelimumab, pembrolizumab+lenvatinib+pemetrexed, pembrolizumab+olaparib, nogapendekin alfa (N-803)+pembrolizumab, tiragolumab+atezolizumab, vibostolimab+pembrolizumab, or ociperlimab+tislelizumab.
• Therapeutic agents used to treat small cell lung cancer include atezolizumab, bendamustime, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, ipillimumab, irinotecan, nivolumab, paclitaxel, temozolomide, topotecan, vincristine, vinorelbine, and any combinations thereof.
• therapeutic agents used to treat SCLC include atezolizumab, carboplatin, cisplatin, etoposide, paclitaxel, topotecan, nivolumab, durvalumab, trilaciclib, or combinations thereof.
• therapeutic agents used to treat SCLC include atezolizumab+carboplatin+etoposide, atezolizumab+carboplatin, atezolizumab+etoposide, or carboplatin+paclitaxel.
• Therapeutic agents used to treat ovarian cancer include 5-flourouracil, albumin bound paclitaxel, altretamine, anastrozole, bevacizumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, exemestane, gemcitabine, ifosfamide, irinotecan, letrozole, leuprolide acetate, liposomal doxorubicin, megestrol acetate, melphalan, olaparib, oxaliplatin, paclitaxel, pazopanib, pemetrexed, tamoxifen, topotecan, vinorelbine, and any combinations thereof.
• Therapeutic agents used to treat pancreatic cancer include 5-FU, leucovorin, oxaliplatin, irinotecan, gemcitabine, nab-paclitaxel (Abraxane®), FOLFIRINOX, and combinations thereof.
• therapeutic agents used to treat pancreatic cancer include 5-FU+leucovorin+oxaliplatin+irinotecan, 5-FU+nanoliposomal irinotecan, leucovorin+nanoliposomal irinotecan, and gemcitabine+nab-paclitaxel.
• Therapeutic agents used to treat prostate cancer include enzalutamide (Xtandi ⁇ ), leuprolide, trifluridine, tipiracil (Lonsurf), cabazitaxel, prednisone, abiraterone (Zytiga ⁇ ), docetaxel, mitoxantrone, bicalutamide, LHRH, flutamide, ADT, sabizabulin (Veru-111), and combinations thereof.
• therapeutic agents used to treat prostate cancer include enzalutamide+leuprolide, trifluridine+tipiracil (Lonsurf), cabazitaxel+prednisone, abiraterone+prednisone, docetaxel+prednisone, mitoxantrone+prednisone, bicalutamide+LHRH, flutamide+LHRH, leuprolide+flutamide, and abiraterone+prednisone+ADT.
• the antibody and/or fusion protein provided herein is administered with one or more therapeutic agents selected from a PI3K inhibitor, a Trop-2 binding agent, CD47 antagonist, a SIRP ⁇ antagonist, a FLT3R agonist, a PD-1 antagonist, a PD-L1 antagonist, an MCL1 inhibitor, a CCR8 binding agent, an HPK1 antagonist, a DGK ⁇ inhibitor, a CISH inhibitor, a PARP-7 inhibitor, a Cbl-b inhibitor, a KRAS inhibitor (e.g., a KRAS G12C or G12D inhibitor), a KRAS degrader, a beta-catenin degrader, a helios degrader, a CD73 inhibitor, an adenosine receptor antagonist, a TIGIT antagonist, a TREM1 binding agent, a TREM2 binding agent, a CD137 agonist, a GITR binding agent, an OX40 binding agent, and a CAR-T cell therapy.
• the antibody and/or fusion protein provided herein is administered with one or more therapeutic agents selected from a PI3K6 inhibitor (e.g., idealisib), an anti-Trop-2 antibody drug conjugate (e.g., sacituzumab govitecan, datopotamab deruxtecan (DS-1062)), an anti-CD47 antibody or a CD47-blocking agent (e.g., magrolimab, DSP-107, AO-176, ALX-148, letaplimab (IBI-188), lemzoparlimab, TTI-621, TTI-622), an anti-SIRP ⁇ antibody (e.g., GS-0189), a FLT3L-Fc fusion protein (e.g., GS-3583), an anti-PD-1 antibody (pembrolizumab, nivolumab, zimberelimab), a small molecule PD-L1 inhibitor (e.g., GS-4224), an anti-CD47
• the antibody and/or fusion protein provided herein is administered with one or more therapeutic agents selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, axicabtagene ciloleucel and brexucabtagene autoleucel.
• one or more therapeutic agents selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB
• Intermediate 1.1 may be reacted with a suitable alkenyl metallated coupling partner (1.2) (where M is —B, —Sn, —Zn, —Si, or —Mg) to produce Intermediate 1.3.
• Intermediate 1.3 may then be reacted under suitable oxidation conditions (e.g. NaIO 4 with catalytic K 2 OsO 4 ⁇ 2H 2 O, O 3 then Me 2 S) to generate Intermediate 1.4.
• Intermediate 2.1 may be reacted with a suitable alkenyl metallated coupling partner (1.2) (where M is —B, —Sn, —Zn, —Si, or —Mg) to produce Intermediate 2.2.
• Intermediate 2.2 may then be reacted under suitable oxidation conditions (e.g. NaIO 4 with catalytic K 2 OsO 4 ⁇ 2H 2 O, O 3 then Me 2 S) to generate Intermediate 2.3.
• Intermediate 2.1 may be reacted with a suitable metallated coupling partner (3.1) (where M is —B, —Sn, —Zn, —Si, or —Mg) to produce Intermediate 3.2.
• suitable conditions e.g. trifluoroacetic acid or methanesulfonic acid followed by DMEDA
• Intermediate 3.3 can then be reacted with a suitable halogenating reagent (e.g., SOCl 2 , POCl 3 , PBr 3 ) to produce an Intermediate 3.4 (where X ⁇ Cl, Br, I).
• Intermediate 4.1 can be reacted with a suitable aldehyde or ketone (4.3) in the presence of a suitable reducing reagent (e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH) to produce Compounds I.a.
• a suitable reducing reagent e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH
• Compounds I.a can be assembled by the combination of Compounds 4.1 with an Intermediate 4.4, where X is a leaving group (e.g. Cl, Br, I, OTs, OMs), in the presence or absence of a base (e.g., N,N-diisopropylethylamine, triethylamine, K 2 CO 3 , CsCO 3 ) in an inert solvent (e.g. DMF, acetonitrile) at r.t. or elevated temperature.
• a base e.g.
• a Compound I.a can be reacted with a suitable aldehyde or ketone (5.1) in the presence of a suitable reducing reagent (e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH) to produce a Compound I.b.
• a suitable reducing reagent e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH
• a Compound 1.b can be assembled by the combination of a Compound I.a with an Intermediate 5.2, where X is a leaving group (e.g.
• a base e.g., N,N-diisopropylethylamine, triethylamine, K 2 CO 3 , CsCO 3
• an inert solvent e.g. DMF, acetonitrile
• a Compound 1.3 can be reacted with a suitable primary or secondary amine (6.1) in the presence of a suitable reducing reagent (e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH) to produce a Compound I.b.
• a suitable reducing reagent e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH
• a Compound 2.3 can be reacted with a suitable primary or secondary amine (6.1) in the presence of a suitable reducing reagent (e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH) to produce a Compound 7.1.
• a suitable reducing reagent e.g., NaBH 4 , Na(OAc) 3 BH, Na(CN) 3 BH
• suitable conditions e.g. trifluoroacetic acid or methanesulfonic acid followed by DMEDA
• a Compound 3.4 (where X ⁇ Cl, Br, or I) can be reacted with a suitable primary or secondary amine (6.1) the presence or absence of a base (e.g., N,N-diisopropylethylamine, triethylamine, K 2 CO 3 , CsCO 3 ) in an inert solvent (e.g. DMF, acetonitrile) at r.t. or elevated temperature to generate a compound I.b.
• a base e.g., N,N-diisopropylethylamine, triethylamine, K 2 CO 3 , CsCO 3
• an inert solvent e.g. DMF, acetonitrile
• Step 1 Preparation of 3-(1-oxo-5-vinylisoindolin-2-yl)piperidine-2,6-dione.
• 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (7.0 g, 21.7 mmol) and Pd(PPh 3 ) 2 Cl 2 (1.52 g, 2.17 mmol) were combined in 1,4-dioxane (87 mL) and tributyl(vinyl)stannane (9.5 mL, 32.5 mmol) was added.
• the mixture was degassed by argon sparging for 5 minutes then the flask sealed and heated to 120° C. for 16 hours.
• Step 2 Preparation of 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbaldehyde (I-1). 3-(1-oxo-5-vinylisoindolin-2-yl)piperidine-2,6-dione (4.5 g, 16.5 mmol) was taken up in THF/water (1:1, 160 mL) and sodium periodate (10.6 g, 49.5 mmol) was added followed by K 2 OsO 4 ⁇ 2H 2 O (152 mg, 0.41 mmol). The reaction was stirred at r.t. for 15 hours.
• Step 1 Preparation of 3-(1-oxo-5-vinylisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)piperidine-2,6-dione.
• K 2 CO 3 (9.14 g, 66.2 mmol) were added to the solution of 3-(5-bromo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (10 g, 22.1 mmol) in dioxane (100 ml).
• Step 2 Preparation of 2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindoline-5-carbaldehyde (I-2).
• Step 1 3-(5-(hydroxymethyl)-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)piperidine-2,6-dione.
• (Tributylstannyl)methanol (1.06 g, 1.5 eq) was added to 3-(5-bromo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (1 g, 1 eq) in DMF (10 mL).
• the solution was degassed with nitrogen, and palladium tetrakistriphenylphosphine (0.265 g, 0.1 eq) was added.
• the vial was sealed and heated to 95° C. for 24 h upon which time LCMS analysis indicated complete consumption of the bromide.
• the mixture was concentrated, adsorbed onto silica gel and chromatographed (eluent: CH 2 Cl 2 /MeOH) to provide the title compound.
• Step 2 3-(5-(hydroxymethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
• 3-(5-(hydroxymethyl)-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (600 mg) was taken up in dichloromethane (5 mL) and TFA (5 mL) added. The mixture was stirred for 1 h and then solvents were removed on a rotary evaporator. Residual TFA was removed by coevaporating 3 ⁇ with toluene.
• Step 3 3-(5-(chloromethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (I-3). 3-(5-(hydroxymethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.385 g, 1 eq) was suspended in dichloromethane (5 mL) and thionyl chloride (0.2 g, 1.2 eq) was added. The vial was sealed and the solution was heated to 50° C. and stirred for 4 h.
• Step 1 Preparation of tert-butyl (R)-(1-benzoylpiperidin-3-yl)carbamate.
• Tert-butyl (R)-piperidin-3-ylcarbamate 300 mg, 1.50 mmol
• dichloromethane 10 mL
• benzoyl chloride 200 ⁇ L, 1.72 mmol
• the reaction mixture was warmed to room temperature and stirred for 15 min.
• the reaction mixture was then diluted with dichloromethane and washed with water.
• the organic layer was dried over sodium sulfate and filtered.
• Step 2 Preparation of (R)-(3-aminopiperidin-1-yl)(phenyl)methanone.
• Tert-butyl (R)-(1-benzoylpiperidin-3-yl)carbamate (356 mg, 1.17 mmol) dissolved in dichloromethane (5 mL) was treated with trifluoroacetic acid (2041 ⁇ L, 26.7 mmol). The reaction mixture was stirred at room temperature for 3 h and then concentrated in vacuo to give (R)-(3-aminopiperidin-1-yl)(phenyl)methanone (I-4).
• ES/MS 205.1 (M+H + ).
• Step 1 Preparation of tert-butyl (1-benzyl-1,2,3,4-tetrahydroquinolin-3-yl)carbamate.
• tert-butyl (1,2,3,4-tetrahydroquinolin-3-yl)carbamate (500 mg, 2.01 mmol) was taken up in 1,2-dichloroethane (10 mL) and benzaldehyde (224 ⁇ L, 2.42 mmol) was added followed by acetic acid (345 ⁇ L, 6.04 mmol). The reaction was stirred at r.t. for 30 minutes then sodium trioacetoxyborohydride was added (1.28 g, 6.04 mmol) and the reaction continued at r.t. for 6 hours.
• Step 2 Preparation of 1-benzyl-1,2,3,4-tetrahydroquinolin-3-amine (I-5).
• tert-butyl (1-benzyl-1,2,3,4-tetrahydroquinolin-3-yl)carbamate (472 mg, 1.39 mmol) was taken up in CH 2 Cl 2 (8 mL) and trifluoracetic acid (2 mL) was added. The reaction was stirred at r.t. for 5 hours then concentrated in vacuo to afford 1-benzyl-1,2,3,4-tetrahydroquinolin-3-amine which was used in subsequent transformations without further purification.
• Step 1 Preparation of tert-butyl (R)-(1-(2-chlorobenzyl)piperidin-3-yl)carbamate.
• Tert-butyl (R)-piperidin-3-ylcarbamate 300 mg, 1.50 mmol
• dichloromethane 10 mL
• 2-chlorobenzaldehyde 220 ⁇ L, 1.96 mmol
• triethylamine 300 ⁇ L, 2.15 mmol
• the reaction mixture was stirred at room temperature for 30 min before sodium triacetoxyborohydride (698 mg, 3.30 mmol) was added.
• Step 2 Preparation of (R)-1-(2-chlorobenzyl)piperidin-3-amine (I-6).
• the title compound was prepared in the same manner as I-4, step 2.
• Step 1 Preparation of (R)-(1-bromoethyl)benzene.
• (1S)-1-phenylethanol (500 mg, 4.09 mmol) dissolved in toluene (6 mL) was cooled to 0° C. and then treated with dropwise addition of phosphorus tribromide (120 ⁇ L, 1.28 mmol).
• the reaction mixture was warmed to room temperature. After stirring for 2 h, the reaction mixture was cooled to 0° C. and quenched by the addition of saturated sodium bicarbonate solution.
• the aqueous phase was then extracted with dichloromethane.
• the organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo to give (R)-(1-bromoethyl)benzene which was used without further purification.
• Step 2 Preparation of tert-butyl ((R)-1-((S)-1-phenylethyl)piperidin-3-yl)carbamate.
• Tert-butyl N-[(3R)-3-piperidyl]carbamate (60 mg, 0.30 mmol) dissolved in acetonitrile (2 mL) was treated with cesium carbonate (293 mg, 0.899 mmol) followed by (R)-(1-bromoethyl)benzene (61 mg, 0.33 mmol).
• the reaction mixture was heated at 50° C. for 2 h. After cooling to room temperature, the reaction mixture was extracted with ethyl acetate and washed with water.
• Step 3 Preparation of (R)-1-((S)-1-phenylethyl)piperidin-3-amine (I-7).
• the title compound was prepared in the same manner as I-4, step 2.
• Step 1 Preparation of tert-butyl (R)-(1-phenylpiperidin-3-yl)carbamate.
• Tert-butyl N-[(3R)-3-piperidyl]carbamate (400 mg, 2.0 mmol) dissolved in dichloroethane (8 mL) was treated with triethylamine (560 ⁇ L, 4.02 mmol), copper acetate (400 mg, 2.2 mmol), and phenyl boronic acid (536 mg, 4.39 mmol).
• the reaction mixture was evacuated and filled with N2 three times before heating at 60° C. under N 2 overnight. After cooling to room temperature, the reaction mixture was washed with 10% methanol in dichloromethane and filtered.
• Step 2 Preparation of (R)-1-phenylpiperidin-3-amine (I-10).
• the title compound was prepared in the same manner as I-4, step 2.
• Step 1 Preparation of tert-butyl ((1R,3S)-3-(phenylamino)cyclohexyl)carbamate.
• tert-butyl ((1R,3S)-3-aminocyclohexyl)carbamate (519 mg, 2.42 mmol), iodobenzene (270 ⁇ L, 2.42 mmol), sodium tert-butoxide (349 mg, 3.63 mmol), Pd 2 (dba) 3 (111 mg, 0.12 mmol), and XantPhos (141 mg, 0.24 mmol) were taken up in toluene (5.0 mL) and the mixture sparged with argon for 5 minutes.
• Step 2 Preparation of (1S,3R)—N 1 -phenylcyclohexane-1,3-diamine (I-13).
• tert-butyl ((1R,3S)-3-(phenylamino)cyclohexyl)carbamate (257 mg, 0.88 mmol) was taken up in CH 2 Cl 2 (2 mL) and trifluoracetic acid (0.5 mL) was added. The reaction was stirred at r.t. for 30 minutes then concentrated in vacuo and purified by column chromatography (eluent: MeOH/CH 2 Cl 2 gradient) to afford (1S,3R)—N 1 -phenylcyclohexane-1,3-diamine.
• ES/MS m/z 191.0 (M+H + ).
• Step-1 Preparation of tert-butyl ((1R,3S)-3-phenoxycyclohexyl)carbamate.
• iodobenzene 225 mg, 1.1 mmol
• tert-butyl ((1R,3S)-3-hydroxycyclohexyl)carbamate 285 mg, 1.32 mmol
• (Ir[dF(CF 3 )ppy] 2 (dtbpy))PF 6 (12.4 mg, 0.01 mmol)
• NiCl 2 ⁇ diglyme (12.1 mg, 0.05 mmol
• 4,4′-Di-tert-butyl-2,2′-dipyridyl (14.8 mg, 0.05 mmol) and, DMF (3 mL) followed by 2,2,6,6-tetramethylpiperidine (0.38 mL, 2.2 mmol).
• the reaction was stirred at room temperature in a photoreactor (450 nm wavelength) for 19 h.
• the reaction mixture was then quenched with water and ethyl acetate was added. It was then filtered through celite to clear the gelatinous material. Filtrate layers were separated, and aqueous layer extracted again with ethyl acetate. Combined organics were washed with water followed by brine and then dried over Na 2 SO 4 .
• the crude product was purified via silica gel chromatography (MeOH/EtOAc/Hexane) to give the title product as a solid.
• Step-2 Preparation of (1R,3S)-3-phenoxycyclohexan-1-amine trifluoroacetic acid salt (I-15).
• Step-1 Preparation of tert-butyl ((1,3-cis)-3-((1H-pyrazol-1-yl)methyl)cyclohexyl)carbamate.
• tert-Butyl ((1,3-cis)-3-(bromomethyl)cyclohexyl)carbamate 700 mg, 2.40 mmol
• K 2 CO 3 (662 mg, 4.79 mmol) were combined in DMF (12 mL) and the reaction was stirred at r.t. overnight. Following this time, the reaction was stopped and Et 2 O and water were added to the reaction. The organic phase was collected and the aqueous phase was extracted with Et 2 O (2 ⁇ ).
• Step-2 Preparation of (1,3-cis)-3-((1H-pyrazol-1-yl)methyl)cyclohexan-1-amine.
• tert-Butyl ((1,3-cis)-3-((1H-pyrazol-1-yl)methyl)cyclohexyl)carbamate (204 mg, 0.730 mmol) was taken up in CH 2 Cl 2 (2 mL) and trifluoroacetic acid (0.5 mL) was added. The reaction was stirred at r.t. for 1 h and then the mixture was concentrated directly to afford the product as the trifluoroacetate salt which was used without further purification.
• Step 1 Preparation of 2,2,2-trifluoro-1-phenylethyl trifluoromethanesulfonate.
• a stirring solution of 2,2,2-trifluoro-1-phenylethan-1-ol (500 mg, 2.84 mmol) in DCM (6 mL) was treated with 2,6-lutidine (0.66 mL, 5.7 mmol), then cooled to 0° C.
• Triflic anhydride 1.0 M in DCM, 5.1 mL, 5.1 mmol
• Step 2 Preparation of tert-butyl ((3R)-1-(2,2,2-trifluoro-1-phenylethyl)piperidin-3-yl)carbamate.
• a solution of 2,2,2-trifluoro-1-phenylethyl trifluoromethanesulfonate (242 mg, 0.787 mmol) in DMF (1 mL) was treated with tert-butyl (R)-piperidin-3-ylcarbamate (473 mg, 2.36 mmol), then stirred at 70° C. for 1 h.
• the reaction mixture was then cooled to r.t., diluted with EtOAc, and washed with water (3 ⁇ ), followed by brine.
• Step 3 Preparation of (3R)-1-(2,2,2-trifluoro-1-phenylethyl)piperidin-3-amine (I-18).
• Tert-butyl ((3R)-1-(2,2,2-trifluoro-1-phenylethyl)piperidin-3-yl)carbamate (226 mg, 0.631 mmol) was dissolved in DCM (2 mL) and treated with TFA (2 mL). The resulting mixture was stirred at r.t. for 1 h, then concentrated under vacuum. The resulting residue was co-evaporated from PhMe (3 ⁇ ) to afford the product as a trifluoroacetate salt.
• Step 2 Preparation of 3-(5-((((S)-1-benzylpyrrolidin-3-yl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. 3-(5-((((S)-1-benzylpyrrolidin-3-yl)amino)methyl)-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (70 mg, 0.124 mmol) dissolved in dichloromethane (2 mL) was treated with trifluoroacetic acid (221 ⁇ L, 2.89 mmol).
• reaction mixture was stirred at room temperature for 2 h and then concentrated in vacuo. The residue was then dissolved in dichloromethane, cooled to 0° C., and treated with triethylamine (100 ⁇ L, 0.717 mmol) followed by N,N′-dimethylethylenediamine (40 ⁇ L, 0.372 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was quenched with 1:1 saturated sodium bicarbonate/water then extracted with 5:1 DCM/isopropanol. The organic layer was dried over sodium sulfate and filtered.
• Step 1 3-(1-oxo-5-((((1,4-cis)-4-phenylcyclohexyl)amino)methyl)isoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione
• I-2 50 mg, 0.124 mmol
• (cis)-4-phenylcyclohexan-1-amine hydrochloride (39.5 mg, 0.186 mmol)
• sodium triacetoxyborohydride 79 mg, 0.373 mmol
• 1,2-dichloroethane (0.50 mL)
• acetic acid 0.007 mL, 0.124 mmol
• Step 2 3-(1-oxo-5-((((1,4-cis)-4-phenylcyclohexyl)amino)methyl)isoindolin-2-yl)piperidine-2,6-dione
• Example 31 A vial was charged with 3-(1-oxo-5-((((1S,4S)-4-phenylcyclohexyl)amino)methyl)isoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl) piperidine-2,6-dione (69.8 mg, 0.124 mmol) and DCM (0.698 mL).
• Trifluoroacetic acid (0.190 mL, 2.48 mmol) was then added, and the reaction was mixed at room temperature for 1 h. Following this time, the reaction was concentrated in vacuo. The residue was then taken up in DCM (0.70 mL) and cooled to 0° C. Triethylamine (0.138 mL, 0.993 mmol) was then added slowly, followed by N,N′-dimethylethylenediamine (0.0160 mL, 0.149 mmol). The reaction was then allowed to warm to room temperature and mixed for 17 h. Following this time, the reaction was concentrated in vacuo.
• Example 49 is a mixture of Example 49(a): 3-(5-((((1R,2R)-2-hydroxycyclohexyl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and Example 49(b): 3-(5-((((1S,2S)-2-hydroxycyclohexyl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione).
• Example 93 is a mixture of Example 93(a): (1R,3R)-3-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)cyclohexane-1-carbonitrile and Example 93(b): (1S,3S)-3-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino) cyclohexane-1-carbonitrile.
• 2,6-dione mixture of (128a) 3-(1-oxo-5-((((1R,3R)-3- (trifluoromethyl)cyclohexyl)amino) methyl)isoindolin-2-yl)piperidine- 2,6-dione and (128b) 3-(1-oxo-5-((((1S,3S)-3- (trifluoromethyl)cyclohexyl)amino) methyl)isoindolin-2-yl)piperidine- 2,6-dione
• Step-1 Preparation of tert-butyl (1,4,6-cis)-6-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.
• I-3 60 mg, 0.21 mmol
• DMF 2 mL
• rel-tert-butyl (1R,4R,6R)-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate 87 mg, 0.41 mmol
• Step-2 Preparation of 3-(5-((((1,4,6-cis)-2-azabicyclo[2.2.1]heptan-6-yl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Example 98).
• reaction mixture was filtered through a syringe filter and purified directly by RP-HPLC (eluent: MeCN/water gradient with 0.1% TFA) to yield the product (Example 150) as the trifluoracetate salt.
• Step 1 tert-Butyl (3S)-3-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-3-methylpiperidine-1-carboxylate.
• tert-Butyl (3S)-3-amino-3-methyl-piperidine-1-carboxylate (87.9 mg, 0.41 mmol) and DIEA (0.29 mL, 1.71 mmol) were added to a stirring solution of I-3 (100 mg, 0.34 mmol) in DMF (3 mL). The resulting solution was heated to 65° C. and stirred overnight. Following this time, the reaction mixture was cooled to r.t. then poured into water.
• Step 2 3-(5-((((S)-3-methylpiperidin-3-yl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
• Trifluoroacetic acid (57 ⁇ L, 0.74 mmol) was added to a stirring solution of tert-butyl (3S)-3-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-3-methylpiperidine-1-carboxylate (70 mg, 0.15 mmol) in CH 2 Cl 2 (5 mL) and the reaction mixture stirred at r.t. for 1 h. The reaction mixture was then concentrated in vacuo to give the title product as the trifluoroacetate salt which was used in the subsequent reaction without further purification.
• Step 3 3-(5-((((S)-1-benzyl-3-methylpiperidin-3-yl)amino)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Example 155).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85076046

Family Applications (1)

Country Status (10)

Families Citing this family (3)

Family Cites Families (329)

• 2022
  • 2022-12-20 US US18/068,700 patent/US20240124412A1/en active Pending
  • 2022-12-20 JP JP2024535416A patent/JP7881713B2/ja active Active
  • 2022-12-20 CA CA3239528A patent/CA3239528A1/en active Pending
  • 2022-12-20 AU AU2022419982A patent/AU2022419982B2/en active Active
  • 2022-12-20 CN CN202280085161.8A patent/CN118488946A/zh active Pending
  • 2022-12-20 WO PCT/US2022/082011 patent/WO2023122581A2/en not_active Ceased
  • 2022-12-20 KR KR1020247024309A patent/KR20240123836A/ko active Pending
  • 2022-12-20 EP EP22847510.9A patent/EP4452414A2/en active Pending
  • 2022-12-21 TW TW111149135A patent/TWI858469B/zh active
  • 2022-12-21 TW TW113135051A patent/TW202500557A/zh unknown
  • 2022-12-22 AR ARP220103555A patent/AR127821A1/es not_active Application Discontinuation
• 2026
  • 2026-03-30 JP JP2026056238A patent/JP2026095542A/ja active Pending
  • 2026-07-14 AU AU2026206059A patent/AU2026206059A1/en active Pending

Non-Patent Citations (3)

Also Published As